WNT activates the AAK1 kinase to promote clathrin-mediated endocytosis of LRP6 and establish a negative feedback loop by Agajanian, Megan J. et al.
UNIVERSIDADE ESTADUAL DE CAMPINAS
SISTEMA DE BIBLIOTECAS DA UNICAMP
REPOSITÓRIO DA PRODUÇÃO CIENTIFICA E INTELECTUAL DA UNICAMP
Versão do arquivo anexado / Version of attached file:
Versão do Editor / Published Version
Mais informações no site da editora / Further information on publisher's website:
https://www.sciencedirect.com/science/article/pii/S2211124718319533
DOI: 10.1016/j.celrep.2018.12.023
Direitos autorais / Publisher's copyright statement:
©2019 by Elsevier. All rights reserved.
DIRETORIA DE TRATAMENTO DA INFORMAÇÃO
Cidade Universitária Zeferino Vaz Barão Geraldo
CEP 13083-970 – Campinas SP
Fone: (19) 3521-6493
http://www.repositorio.unicamp.br
ArticleWNTActivates the AAK1Kinase to Promote Clathrin-
Mediated Endocytosis of LRP6 and Establish a


















Kinome gain-of-function and loss-of-function 
screens of the WNT signaling pathway 


























ULK4Highlightsd Gain-of-function kinome screen identifies AAK1 as a
repressor of WNT signaling
d AAK1 promotes clathrin-mediated endocytosis of LRP6
d Selective AAK1 inhibitor stabilizes b-catenin and activates
WNT signaling
d WNT induces AAK1-dependent phosphorylation of AP2M1
and LRP6 endocytosisAgajanian et al., 2019, Cell Reports 26, 79–93
January 2, 2019 ª 2018 The Authors.
https://doi.org/10.1016/j.celrep.2018.12.023Authors
Megan J. Agajanian, Matthew P. Walker,
Alison D. Axtman, ..., Timothy M. Willson,




WNT signal transduction is essential for
normal development and contributes to
many human diseases. Agajanian et al.
used a kinase gain-of-function screen to
show thatWNT activates the AAK1 kinase
to promote clathrin-mediated
endocytosis of the WNT receptor. This
work identifies an AAK-driven negative
feedback loop that downregulates WNT
signaling.
Cell Reports
ArticleWNT Activates the AAK1 Kinase to Promote
Clathrin-Mediated Endocytosis of LRP6
and Establish a Negative Feedback Loop
Megan J. Agajanian,1,2,12 Matthew P. Walker,1,12 Alison D. Axtman,3,4,12 Roberta R. Ruela-de-Sousa,5,12
D. Stephen Serafin,1,6 Alex D. Rabinowitz,1 David M. Graham,6 Meagan B. Ryan,1,2 Tigist Tamir,1,2 Yuko Nakamichi,1,7
Melissa V. Gammons,8 James M. Bennett,9 Rafael M. Couñago,5 David H. Drewry,3,4 Jonathan M. Elkins,5,9
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b-Catenin-dependent WNT signal transduction gov-
erns development, tissue homeostasis, and a vast
array of human diseases. Signal propagation through
a WNT-Frizzled/LRP receptor complex requires pro-
teins necessary for clathrin-mediated endocytosis
(CME). Paradoxically, CME also negatively regulates
WNT signaling through internalization and degrada-
tion of the receptor complex. Here, using a gain-of-
function screen of the human kinome, we report
that the AP2 associated kinase 1 (AAK1), a known
CME enhancer, inhibits WNT signaling. Reciprocally,
AAK1 genetic silencing or its pharmacological inhibi-
tion using a potent and selective inhibitor activates
WNT signaling. Mechanistically, we show that AAK1
promotes clearance of LRP6 from the plasma mem-
brane to suppress the WNT pathway. Time-course
experiments support a transcription-uncoupled,
WNT-driven negative feedback loop; prolonged
WNT treatment drives AAK1-dependent phosphory-
lation of AP2M1, clathrin-coated pit maturation, and
endocytosis of LRP6. We propose that, following
WNT receptor activation, increased AAK1 function
and CME limits WNT signaling longevity.This is an open access article under the CC BY-NINTRODUCTION
b-Catenin-dependent WNT signal transduction is an evolution-
arily conserved pathway that instructs cell and tissue-specific
differentiation and proliferation programs. It is required for both
normal development andmaintenance of adult tissue homeosta-
sis (Nusse and Clevers, 2017). Like many developmental
signaling pathways, aberrant WNT signaling contributes funda-
mentally to human diseases, including cancer, bone density dis-
orders, and neurodegeneration (Nusse and Clevers, 2017). The
regulation of theWNT/b-catenin signaling axis is often described
in three stages: proximal signaling, b-catenin destruction, and
nuclear effectors of transcription (Angers and Moon, 2009). In
the absence of WNT ligand, the LRP5/6 (low-density lipoprotein
receptor related protein 5/6) and Frizzled (FZD) family of WNT re-
ceptors remain dissociated. Within the cytosolic compartment, a
multi-protein b-catenin destruction complex comprises AXIN1/
2, APC (adenomatous polyposis coli), CK1a (casein kinase 1a),
and GSK3b (glycogen synthase kinase 3b). CK1a and GSK3b
sequentially phosphorylate b-catenin, resulting in its ubiquityla-
tion by b-TRCP and ultimately proteasomal degradation (Her-
nández et al., 2012; Liu et al., 1999, 2002; Zeng et al., 2005).
Extracellular WNT ligand physically couples LRP5/6 and FZD re-
ceptors, leading to phosphorylation-dependent recruitment of
the DVL (Dishevelled1/2/3), GSK3b, AXIN1/2, and adenomatous
polyposis coli proteins (Bilic et al., 2007; Mao et al., 2001; Met-
calfe et al., 2010; Tamai et al., 2000). This complex, referred toCell Reports 26, 79–93, January 2, 2019 ª 2018 The Authors. 79
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
as the WNT signalosome, transiently suppresses b-catenin
phosphorylation by GSK3b (Bilic et al., 2007). Hence, WNT
ligand transiently inactivates the destruction complex to pro-
mote cytoplasmic accumulation of b-catenin, resulting in its
translocation to the nucleus, where it binds to members of the
TCF/LEF family of transcription factors to modulate tissue-spe-
cific transcriptional programs and cell phenotypes (Behrens
et al., 1996).
Through a gain-of-function screen of the kinome, we discov-
ered that the AP2 associated kinase 1 (AAK1) kinase negatively
regulates b-catenin-dependent WNT signaling by promoting cla-
thrin-mediated endocytosis (CME) of LRP6. CME is a complex
and multi-step process that removes lipids and transmembrane
proteins from the plasma membrane. The assembly polypeptide
2 (adaptor-related protein 2 [AP2]) protein complex first recog-
nizes and binds sorting signals on the intracellular domains of
transmembrane cargo proteins (Höning et al., 2005; Ricotta
et al., 2002). Activation of the AP2 machine occurs allosterically
through binding cargo, clathrin, and PIP2 (phosphatidylinositol
4,5-bisphosphate) (Kadlecova et al., 2017). This activation coin-
cides with a conformational shift in AP2 from ‘‘closed’’ to ‘‘open.’’
Open/active AP2 is required for continued clathrin polymeriza-
tion, cargo recruitment, and ultimately the maturation of a
nascent clathrin-coated pit to a stable, successful endocytic
event (Conner and Schmid, 2002; Conner et al., 2003; Hender-
son and Conner, 2007; Kadlecova et al., 2017; Ricotta et al.,
2002). In addition to PIP2, cargo, and clathrin, activation of the
AP2 complex is promoted by phosphorylation of the AP2M1
subunit by AAK1 (Conner and Schmid, 2002; Conner et al.,
2003; Henderson and Conner, 2007; Kadlecova et al., 2017;
Ricotta et al., 2002). Importantly, AAK1-dependent phosphoryla-
tion of AP2M1 is promoted by clathrin assembly (Conner et al.,
2003), which constitutes a positive feedforward loop to promote
pit maturation. Once mature, cargo-loaded clathrin-coated pits
evolve to endosomal vesicles through dynamin-mediated scis-
sion from the plasma membrane (Damke et al., 1994).
Numerous studies establish a regulatory role for CME in WNT
signaling, although whether CME activates or inhibits signaling
remains debated (Blitzer and Nusse, 2006; Hagemann et al.,
2014; Jiang et al., 2012; Kim et al., 2013; Yamamoto et al.,
2008). However, a specific role for AAK1 in WNT signaling has
not previously been reported. First, clathrin, AP2, and PIP2 are
required for WNT-induced LRP6 phosphorylation, signalosome
formation, and subsequent WNT signaling (Bilic et al., 2007;
Kim et al., 2013). AP2 and clathrin recruitment to theWNT signal-
osome is induced by WNT ligand, presumably via WNT-induced
PIP2 production (Kim et al., 2013). Indeed, WNT ligand induces a
gradual accumulation of PIP2 over a 4 hr window after treatment
with WNT ligand (Pan et al., 2008). These studies suggest that
clathrin-associated machinery is required for WNT-induced sig-
nalosome maturation and maintenance and, although not yet
proved, possibly for its formation. Second, Gammons et al.
(2016a) established that the WNT signalosome incorporates
into clathrin-coated pits via DVL polymerization and that this is
ultimately required for signalosome formation and WNT signal
transduction. Third, De Robertis and colleagues described a
mechanism by which the endocytosed signalosome is incorpo-
rated into multivesicular bodies (MVBs). Here, sequestration of80 Cell Reports 26, 79–93, January 2, 2019GSK3b in MVBs suppresses b-catenin phosphorylation, thus
potentiating signaling (Taelman et al., 2010). Finally, others
have reported that CME of LRP6 and FZD downregulates WNT
signaling (Hao et al., 2012; Jiang et al., 2012; Koo et al., 2012;
Liu et al., 2014; Yamamoto et al., 2008). For example, disabled
homolog 2 (DAB2) drives LRP6 toward CME and represses
WNT signaling (Jiang et al., 2012). Additionally, phosphorylation
of LRP6 on cytoplasmic tyrosine residues drives CME of LRP6,
resulting in decreased WNT signaling (Liu et al., 2014). Further-
more, ubiquitylation of FZD by ZNRF3 and RNF43 drives recep-
tor internalization and degradation, resulting in decreased WNT
signaling (Hao et al., 2012; Koo et al., 2012). All together, these
studies establish CME as a major regulatory feature in WNT
signaling. Although still unresolved, it is likely contextual and
temporal considerations play an important role in determining
either a positive or negative role for CME in WNT signaling.
Cross-referencing our gain-of-function screen of the kinome
with previously published loss-of-function screens, we identify
AAK1 as a negative regulator of WNT-induced b-catenin tran-
scription. Gain- and loss-of-function studies reveal that AAK1
negatively regulates WNT signaling by promoting CME of
LRP6; FZD remains to be tested.We also report and use a potent
and selective cell active AAK1 inhibitor, which potentiates WNT
signaling. Full characterization of this small molecule establishes
it as the best available tool compound to interrogate AAK1
biology. Unexpectedly, we discovered that WNT induces phos-
phorylation of AP2M1 by AAK1 in a temporally delayed fashion
at 8–10 hr post-WNT3A treatment. Therefore, we propose a
modified model whereby WNT-driven CME promotes a negative
feedback mechanism to limit pathway longevity. Indeed, we
show that WNT stimulation promoted CME of LRP6 in an
AAK1-dependent fashion. More broadly, this work contributes
to the ongoing discussion of endocytosis within WNT signaling
by solidifying a role for the AAK1 kinase in removing LRP6
from the cell plasma membrane.
RESULTS
Identification of AAK1 as a Repressor of WNT Signaling
Thirty years of research on the WNT pathway has revealed its
core components and basic mechanics. That said, recent im-
provements in genetic screening technologies and protein
mass spectrometry continue to identify additional modifiers of
WNT pathway activity. We, along with others, have reported
genome-wide gain- and loss-of-function genetic screens of the
WNT pathway, illuminating regulators (e.g., FOXP1, USP6,
TFAP4) and their mechanisms of WNT control (Lebensohn
et al., 2016; Madan et al., 2016; Walker et al., 2015). Here, we
focused on the human kinome to determine which kinases
when overexpressed activate or inhibit WNT3A-driven b-catenin
transcription. We cloned 387 kinase open reading frames (ORFs)
into a lentiviral expression vector before transient overexpres-
sion in HEK293T cells carrying the b-catenin-activated Firefly
luciferase reporter (BAR) and a constitutively expressed Renilla
(Ren) luciferase. Eighteen hours after kinase transfection, cells
were treated with WNT3A conditioned media (CM) for an addi-
tional 16 hr before lysis and BAR/Ren reporter quantitation
(Table S1). ANKRD6/Diversin and CTNNB1/b-catenin served
as positive controls for repression and activation, respectively.
Five kinases (AAK1, ADCK1, ADCK2, MAST1, and TGFBR3)
were validated by low-throughput reporter assays in HEK293T-
BAR/Ren cells (Figure 1A). Comparative analysis of this kinome
gain-of-function screen in HEK293T cells with two previously
published small interfering RNA (siRNA)-based loss-of-function
screens in HT1080 sarcoma cells and A375 melanoma cells re-
vealed a single common protein: AAK1 (Table S1) (Biechele
et al., 2012; Madan et al., 2016). Because of the well-established
functional connections between AAK1 and CME and the
emerging data on CME in governing WNT pathway dynamics,
we sought to understand how AAK1 negatively regulates the
WNT pathway.
To validate and extend the discovery of AAK1 as a WNT inhib-
itor, we tested (1) whether siRNA-mediated silencing of AAK1
activated b-catenin-driven transcription, (2) the cell-type speci-
ficity of the AAK1-WNT phenotype, (3) whether AAK1 regulated
the expression of endogenous b-catenin target genes, and (4)
whether AAK1 affected the activity of non-WNT signaling path-
ways. First, in agreement with AAK1 overexpression blocking
WNT signaling (Figure 1A), siRNA silencing of AAK1 using two
non-overlapping siRNAs increased BAR expression in HT1080
fibrosarcoma cells and RKO colon cancer cells (Figures 1B
and 1C). To visualize reporter expression in real time, we
silenced AAK1 in HT1080 cells carrying a BAR-mCherry reporter.
Quantitation of mCherry fluorescence confirmed that AAK1
knockdown activated the BAR reporter (Figure 1D), while AAK1
overexpression suppressed BAR activity (Figure 1E). Third, to
rule out potential reporter-based artifacts, we quantified the
expression of two endogenous WNT target genes after AAK1
perturbation. AAK1 knockdown increased RNA expression of
AXIN2 and NKD1 in both HEK293T and HT1080 cells (Figures
1F and 1G). Conversely, AAK1 overexpression led to decreased
RNA expression of AXIN2 and NKD1 in HEK293T cells (Fig-
ure 1H). Fourth, because of its established roles in CME, AAK1
might broadly regulate other signaling cascades. AAK1 overex-
pression did not affect TNFa-driven NFkB reporter activity or
TGFb-driven SMAD reporter activity (Figure 1I). Together, these
data establish that AAK1 negatively regulates WNT signaling in
cells derived from multiple tissue types. Importantly and consis-
tent with its established role in CME, AAK1 did not affect b-cat-
enin transcriptional activity in the absence of exogenous WNT3A
stimulation.
Discovery of a Potent and Selective Inhibitor of AAK1
Indazole compound SB-742864 was previously identified as a
semi-selective inhibitor of AAK1 (in vitro half maximal inhibitory
concentration [IC50] = 220 nM) (Elkins et al., 2016). Optimization
of SB-742864 via iterative medicinal chemistry optimization led
to compound 25A (Figure 2A), a potent and selective inhibitor
of AAK1 and the closely related kinaseBMP2K. Further optimiza-
tion to improve the selectivity led to SGC-AAK-1 (Figure 2A), a
chemical probe for AAK1 and BMP2K. A closely related mole-
cule, SGC-AAK1-1N (referred to as 34A), which is devoid of ac-
tivity on AAK1 or BMP2K, was identified for use as a negative
control compound. Full details of the chemistry program and
analysis of the structure-activity relationships will be published
elsewhere. Compounds 25A and SGC-AAK-1, but not 34A,both selectively inhibited AAK1 and BMP2K over the other mem-
bers of the subfamily, Numb-associated kinases GAK and
STK16, in a TR-FRET binding displacement assay (Figures 2B
and S1A), with Ki values against AAK1 of 8 and 9 nM respectively
for 25A and SGC-AAK1-1 and 2 mM for negative control 34A.
Both 25A and SGC-AAK1-1 showed good selectivity over a
panel of 406 wild-type protein human protein kinases at 1 mM
concentration (Figures 2C and S1B; Table S2) with only a small
number of other kinases inhibited with dissociation constant
(BMP2K KD bound to 25A) values within 30 times of those of
AAK1. Kinases that exhibited >85% inhibition and/or are com-
mon kinase off-targets of acylaminoindazoles within this struc-
tural class were analyzed to determine whether the inhibition
was confirmed in a dose-dependent KD determination experi-
ment. Kinases for which the compound of interest demonstrated
a KD < 100 nM are marked with a large red circle and 100 nM <
KD < 1.0 mM with a smaller red circle. One of these kinases,
PIP5K1C, is required for PIP2 production, which plays a key
role in regulating WNT signaling. To ensure that any observed
phenotype is AAK1 dependent, we determined the PIP5K1C
IC50 values for SGC-AAK1-1 and 34A as 6.6 and 3.6 mM, respec-
tively, in a PIP5K1C enzyme assay at Reaction Biology (Anastas-
siadis et al., 2011) (Table S3). The in vitro IC50 values for inhibition
of AAK1 enzymatic activity were determined for SGC-AAK1-1
and the negative control (34A) versus a positive control (stauro-
sporine) using a coupled enzyme assay system. Inhibition of
AAK1 enzymatic activity was confirmed for SGC-AAK1-1
(IC50 = 270 nM). The controls demonstrated the expected activity
profiles: 34A was not active (IC50 > 1 mM), while staurosporine
demonstrated potent AAK1 inhibition (IC50 = 120 nM) (Fig-
ure S1C). Isothermal titration calorimetry (ITC) measured KD
values for SGC-AAK1-1 of 120 and 490 nM against AAK1 and
BMP2K, respectively, and showed that binding had favorable
enthalpy (DH) and unfavorable entropy (TDS) (Figures 2D and
S1D; Table S4). Attempts to co-crystallize either inhibitor with
AAK1were unsuccessful, but it was possible to obtain a co-crys-
tal structure of 25A with BMP2K to 2.41 Å resolution (Figures 2E,
S1E, and S1F; Table S5). The structure revealed 25A bound in
the ATP site, making three hydrogen bonds to the kinase hinge
region and two further hydrogen bonds via its sulfonamide oxy-
gens to Gln137 and Asn185, while the central hydrophobic
portion of the inhibitor packs against the gatekeeper residue
Met130. Hydrogen bonds are indicated as dashed lines to the
respective residues within the BMP2K binding pocket (Fig-
ure 2E). All pertinent statistics associated with data collection
for the BMP2K co-crystal structure, the full-length structure
with 25A bound, and the electron density map are included in
the Supplemental Information (Table S5; Figures S1E and S1F).
To test that the inhibitors engage AAK1 and BMP2K in live
cells, we used NanoBRET assays (Promega) (Vasta et al.,
2018), in which human cells were transfected with a plasmid
expressing the full-length kinase gene fused to Nanoluc lucif-
erase. In the presence of a fluorescent-labeled ATP-competitive
tracer compound, a bioluminescence resonance energy transfer
(BRET) signal was measured. Displacement of the tracer by the
inhibitor being tested, resulting in loss of BRET, demonstrated
target engagement, and linear regression of the IC50 values at
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Figure 1. Gain-of-Function Kinome Screen Reveals AAK1 as a Repressor of WNT Signaling
(A) HEK293T-B/R cells were transfected with the indicated construct for 24 hr. Cells were then treated for 16 hr with WNT3A or Lcell CM. Bars represent average
Firefly/Ren relative fluorescence units (RFU) from three technical replicates.
(B and C) Luciferase assay of HT1080 (B) or RKO (C) stable B/R cells transfected with either control or AAK1 siRNA for 56 hr. Cells were then treated with either
Lcell or WNT3A CM for 16 hr. Bars represent average Firefly/Ren RFU from three technical replicates. Western blot analysis illustrates knockdown efficiency of
two independent AAK1 siRNAs.
(D) IncuCyte imaging of HT1080 cells stably expressing a BAR-mCherry fluorescent reporter transiently transfected with indicated siRNA construct. WNT3A CM
was added at 18 hr, then cells were imaged for 50 hr post-transfection. Graph represents data points averaged across four technical replicates.
(E) Live-cell imaging of HT1080 cells stably expressing a BAR-mCherry fluorescent reporter transiently transfected with the indicated expression construct,
AAK1, or FLAG control. WNT3A CM was added at 8 hr, and cells were monitored for an additional 56 hr. Data represent the average of four technical replicates.
(F and G) qPCR analysis of AXIN2 and NKD1 in HEK293T (F) or HT1080 (G) cells 72 hr after transfection with the indicated siRNA. Cells were treated with WNT3A
CM for 6 hr prior to harvest. Bars represent average glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-normalized gene expression across three technical
replicates.
(H) qPCR analysis of AXIN2 (left) andNKD1 (right) in HEK293T cells transfected with overexpression construct for 24 hr, then treated withWNT3A CM for 6 hr prior
to harvest. Bars represent average GAPDH-normalized gene expression across three technical replicates.
(I) Luciferase assay of HEK293T cells transfected with indicated pathway-specific Firefly luciferase reporter constructs and expression constructs prior to a 16 hr
treatment with recombinant human (rh) WNT3A (200ng/mL), rhTNFa (200ng/mL), or rhTGFb1 (200ng/mL). Bars represent average Firefly/Ren RFU from three
technical replicates.
*p < 0.05, **p < 0.005, and ***p < 0.0005. All data are representative of biological triplicates, unless otherwise noted. Error bars represent SE.
For complete statistics, see STAR Methods. See also Table S1.








































































































































































Figure 2. SGC-AAK1-1 Is a Potent and Specific Inhibitor of AAK1 and BMP2K
(A) Chemical structures of the AAK1/BMP2K chemical probe SGC-AAK-1, the related AAK1/BMP2K inhibitor 25A, and the negative control compound 34A that
has a similar chemical structure but does not inhibit AAK1 or BMP2K.
(B) SGC-AAK-1 selectively bound AAK1 and BMP2K with a more than 30-fold difference in Ki in a TR-FRET binding displacement assay over the related kinases
GAK and STK16. Sixteen-point dose-response curves were measured in duplicate.
(C) SGC-AAK1-1 has good selectivity over the human kinome. SGC-AAK1-1 was used at 1 mM concentration and tested against over 400 wild-type human
kinases. KD determination was completed for all kinases that exhibited >85% inhibition and/or were observed as common off-targets for this structural class.
Kinases for which SGC-AAK1-1 has a KD < 100 nM are marked with a large red circle and 100 nM < KD < 1.0 mM with a smaller red circle.
(D) ITC confirmed a KD of 120 nM for binding of SGC-AAK1-1 to AAK1.
(E) A co-crystal structure of BMP2K (2.41 Å) bound to 25A revealed the binding mode of the inhibitor in the ATP site. This structure revealed five key hydrogen
bonds and revealed the orientation of the central hydrophobic portion of the inhibitor with respect to the binding pocket.
(F andG) NanoBRET cellular target engagement assays in HEK293T cells showed that 25A (F) and SGC-AAK1-1 (G) both entered cells and directly bound to AAK1
and displaced a fluorescent tracermolecule from the ATP site. Cells were treatedwith serially diluted inhibitors in the presence of four different concentrations of a
NanoBRET tracer molecule, and IC50 values were calculated from a linear interpolation of the IC50 values at each tracer concentration to obtain the predicted IC50
in the absence of tracer. Measurements were made with three technical replicates.
(H) Binding of SGC-AAK1-1 to BMP2K in cells was weaker than to AAK1 with IC50 > 1 mM. Displacement of the same fluorescent tracer molecule required
increased concentrations of SGC-AAK1-1, revealing an elevated IC50 value for binding to BMP2K versus AAK1 in the cellular target engagement assay.
(I) SGC-AAK1-1 inhibited the phosphorylation of the AP2M1 subunit at Thr156 in HEK293T cells in a concentration-dependent manner or with 10 mM 34A.
HEK293T cells were treated with inhibitors for 2 hr before western blot analysis.
Error bars represent SE. See also Figure S1 and Tables S2, S3, S4, and S5.
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Figure 3. AAK1 Inhibition Potentiates WNT Signaling and Stabilizes b-Catenin
(A) Representative western blot of HT1080 cells treated with indicated compounds (2.5 mM) for 1 hr (left). Box-and-whisker plot represents quantification of four
biological replicate experiments using LiCOR software (right).
(B) BAR luciferase assay of HT1080-B/R stable cells treated with WNT3A CM and the indicated dose of compound for 16 hr. Data are averaged over three
technical replicates.
(C) qPCR analysis ofAXIN2 orNKD1 fromHT1080 cells treatedwith indicated compound (1.25 mM) for 12 hr in the presence of Lcell orWNTCMand normalized to
GAPDH. Graph represents analysis averaged across three technical replicates.
(D and E) Western blot analysis of RKO cells following a 15 min WNT3A pulse, then treated with 1.25 mM of either 34A or SGC-AAK1-1 for the indicated time.
Dashed line (D) represents cropped blot for removal of redundant, untreated sample.
*p < 0.05, **p < 0.005, and ***p < 0.0005. All data are representative of biological triplicates, unless otherwise noted. Error bars represent SE. For complete
statistics, see STAR Methods.of tracer. 25A and SGC-AAK-1 bound to AAK1 in HEK293T cells
with IC50 values of about 240 nM, and more weakly to BMP2K,
with IC50 values of 600 nM and 1.5 mM, respectively (Figures
2F–2H and S1G). To demonstrate that binding to AAK1 inhibited
its enzymatic activity in cells, phospho-AP2M1 (Thr156) levels
were observed by western blotting after 2 hr treatment of
HEK293T cells with serially diluted SGC-AAK1-1, resulting in a
dose-dependent decrease of pAP2M1 starting below 1 mM, in
agreement with the NanoBRET data (Figure 2I).
AAK1 Inhibitor Activates WNT Signaling by Stabilizing
b-Catenin Levels
To confirm and extend these data, we next tested SGC-AAK1-
1 and 25A in a series of experiments to evaluate its potency of
AAK1 inhibition in cells and regulation of WNT signaling. First,
we treated HT1080 cells with SGC-AAK1-1 and evaluated
AAK1-dependent phosphorylation of AP2M1. SGC-AAK1-1,
along with 25A, both significantly reduced phosphorylation
of AP2M1 (T156), compared with DMSO control and the nega-
tive control, 34A (Figure 3A). Second, treatment with SGC-
AAK1-1 or 25A activated WNT-driven BAR activity compared
with controls (DMSO and 34A) in a dose-dependent manner
(Figure 3B). Importantly, 25A also significantly upregulated84 Cell Reports 26, 79–93, January 2, 2019WNT endogenous target genes AXIN2 and NKD1 in HT1080
cells, compared with DMSO control and 34A (Figure 3C).
Finally, we measured b-catenin protein abundance following
a 15 min pulse of WNT3A ligand in the presence of control
compound 34A or SGC-AAK1-1. In cells pulsed with WNT3A
and cultured with 34A, b-catenin protein levels increased,
reaching a maximum at about 7 hr before returning to baseline
at 18 hr (Figures 3D and 3E). In the presence of SGC-AAK1-1,
b-catenin protein accumulated more robustly at earlier time
points and was sustained throughout the 24 hr time course
(Figures 3D and 3E). Together, these results indicate that
25A and SGC-AAK1-1 block AAK1 kinase activity, resulting
in increased b-catenin protein stability and b-catenin-depen-
dent transcription.
AAK1 Promotes CME of LRP6 to Inhibit WNT Signaling
Several recent studies report that CME negatively regulates
WNT signaling by reducing the presence of the receptor complex
on the plasma membrane (Jiang et al., 2012; Liu et al., 2014; Ya-
mamoto et al., 2008). Given the well-established role of AAK1 in
phosphorylating AP2M1 to facilitate CME (Conner and Schmid,
2002; Conner et al., 2003; Henderson and Conner, 2007; Ricotta
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Figure 4. AAK1 Represses b-Catenin-Medi-
ated WNT Signaling through Regulation of
Endocytosis
(A) HT1080-B/R cells were transfected with indi-
cated siRNA for 56 hr and then treated with WNT3A
or CHIR99021 (1 mM) for 16 hr (left). HT1080-B/R
cells were transfected with the indicated over-
expression DNA construct and allowed to recover
for 12 hr. Cells were then treated withWNT3A CM or
CHIR99021 (1 mM) for 16 hr (right). Data are aver-
aged over three technical replicates.
(B) BAR luciferase assay from HT1080 cells
transiently transfected with BAR-firefly luciferase,
TK-Ren, and the indicated expression constructs.
Twelve hours post-transfection, cells were treated
for 16 hr with Lcell or WNT3A CM and then assayed
for BAR activity. Western blot of FLAG-AAK1 and
FLAG-GFP is shown to illustrate expression of AAK1
constructs. Presented data are averaged across
three technical replicates.
(C) Luciferase assay in HT1080-B/R cells trans-
fected with indicated siRNAs for 50 hr, then co-
transfected with indicated expression constructs for
12 hr. Cells were then treated for 16 hr with either
Lcell or WNT3A CM. Data are averaged over three
technical replicates. Right: western blot of clathrin,
indicating knockdown efficiency.
(D) Luciferase assay of HT1080-B/R cells trans-
fected with indicated siRNA for 56 hr, then treated
as indicated for 16 hr. Data are averaged over three
technical replicates.
(E) Luciferase assay of HEK293T-B/R cells trans-
fected with indicated constructs for 12 hr, then
treated with either Lcell or WNT3A CM for 18 hr.
b-Catenin pm (point mutant) is a construct with the
GSK3b target residues (S33/S37/T41) on b-catenin mutated. Western blot analysis of FLAG and GFP shown to confirm expression of overexpression constructs.
Data are averaged over three technical replicates.
*p < 0.05, **p < 0.005, and ***p < 0.0005. All data are representative of biological triplicates, unless otherwise noted. Error bars represent SE. For complete
statistics, see STAR Methods.
See also Figure S2.WNT signaling is not entirely unexpected. That said, AAK1 has
not previously been shown to regulate WNT signaling, and
certainly, the molecular mechanisms governing CME within the
WNT pathway and its homeostasis are not well defined, with
several remaining questions and conflicting studies (Blitzer and
Nusse, 2006; Gammons et al., 2016a; Hagemann et al., 2014;
Jiang et al., 2012; Liu et al., 2014; Taelman et al., 2010; Yama-
moto et al., 2008). To confirm that AAK1 functions within mem-
brane proximal steps of WNT signaling, we stabilized b-catenin
protein levels with a GSK3b inhibitor (CHIR99021) following
either AAK1 overexpression or siRNA silencing. CHIR99021-
mediated activation of the BAR reporter was not affected by
AAK1 depletion or overexpression (Figure 4A). As expected,
b-catenin knockdown blocked BAR activation by AAK1 silencing
(Figure S2A). These results indicate that AAK1 functions up-
stream of b-catenin and the destruction complex. Next, the
role of endocytosis in AAK1-mediated repression of WNT
signaling was evaluated using two AAK1 mutants: (1) AAK1-
74A, which lacks kinase activity, and (2) AAK1-AID, which
encodes a truncated form of AAK1 that does not bind the AP2
complex (Conner and Schmid, 2002). Neither AAK1-74A nor
AAK1-AID significantly repressed the BAR reporter (Figure 4B),suggesting that both AP2 interaction and kinase activity are
required for AAK1-mediated repression of WNT signaling. A
role for clathrin and CME in AAK1-driven WNT suppression
was tested by (1) siRNA silencing of clathrin, (2) pharmacological
inhibition of clathrin-coated vesicles, and (3) blocking dynamin1
function with an established dominant-negative K44A mutation.
Two non-overlapping clathrin siRNAs effectively silenced cla-
thrin expression and blocked AAK1-dependent suppression of
the BAR reporter in HT1080 cells (Figure 4C). Similarly, treatment
with chlorpromazine, an established, albeit promiscuous CME
inhibitor (Blitzer and Nusse, 2006; Phonphok and Rosenthal,
1991; Wang et al., 1993) suppressed WNT signaling induced
by AAK1 silencing (Figure 4D). Furthermore, co-transfection of
AAK1 and dominant-negative dynamin (DNM1) (K44A) rescued
the AAK1-induced suppression of BAR activity in a dose-depen-
dent manner (Figure 4E). These experiments suggest that AAK1
represses WNT signaling in a clathrin- and kinase-dependent
manner.
We next examined the effect of AAK1 on LRP6 protein levels
using cell surface biotinylation assays and flow cytometry.
AAK1 overexpression decreased LRP6 protein levels at the
plasma membrane (Figure 5A). Additionally, AAK1 knockdownCell Reports 26, 79–93, January 2, 2019 85
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Figure 5. AAK1 Downregulates LRP6 Cell Surface Levels
(A and B) Western blot analysis of HEK293T cells transfected with an AAK1 overexpression construct for 24 hr (A) or AAK1 siRNA for 72 hr (B) prior to membrane
fractionation using a surface biotinylation assay. Data represent average surface staining of four biological replicate experiments quantified by LiCOR software.
(C) LiCOR quantification of western blot analysis of LRP6 levels with AAK1 knockdown. The box-and-whisker plot represents total LRP6 expression normalized to
b-tubulin (loading control) from six biological replicates quantified by LiCOR software.
(D and E) LRP6 surface staining as detected by flow cytometry analysis in HEK293T cells transfected with an AAK1 overexpression construct for 24 hr (D) or an
AAK1 siRNA construct for 72 hr (E). All experiments were quantified using FlowJo software. Experiment was performed in four biological replicates.
(F) LRP6 surface levels as detected by flow cytometry analysis in HEK293T cells treated as indicated for 8 hr. The box-and-whisker plot represents LRP6 surface
levels normalized to BSA control for biological triplicates. Raw values for each experiment are shown in Table S6.
(G) HEK293T cells were transfected with FLAG-AAK1 or FLAG-GFP overexpression constructs. Twenty-four hours post-transfection, cells were treated for 6 hr
with the autophagy inhibitor bafilomycin A1 (100 nm) or DMSO control prior to cell harvest, then analyzed using western blot for endogenous LRP6 and AAK1
levels. The box-and-whisker plot represents LRP6 expression normalized to b-tubulin from four biological replicates quantified by LiCOR software.
*p < 0.05 and **p < 0.005. All data are representative of biological triplicates, unless otherwise noted. For complete statistics, see STAR Methods.
See also Figure S3 and Table S6.by siRNA increased LRP6 surface expression levels (Fig-
ure 5B). On the basis of the observation that total LRP6 levels
seem to decrease with AAK1 knockdown (Figure 5B), we
quantified total LRP6 expression across six biological repli-
cates and demonstrate that with AAK1 knockdown, total
LRP6 levels increase (Figure 5C). To validate the changes in
surface LRP6 expression findings in an orthogonal assay, we
used flow cytometry to quantify cell surface LRP6 levels in
HEK293T cells. Here, AAK1 overexpression decreased LRP6
surface levels while AAK1 knockdown increased LRP6 surface
levels (Figures 5D and 5E). Importantly, LRP6 surface levels
decreased following WNT3A treatment; this decrease was
rescued by co-treatment with the active AAK1 inhibitor
SGC-AAK1-1, but not the negative control compound 34A
(Figure 5F; Table S6). Together, these data indicate that86 Cell Reports 26, 79–93, January 2, 2019WNT3A treatment decreases LRP6 cell surface levels via an
AAK1-dependent mechanism.
We next tested whether AAK1 and LRP6 co-complexed.
Using HEK293T cells, immunoprecipitation, and western blot
analysis of HA-LRP6 protein complexes revealed the presence
of overexpressed FLAG-AAK1 (Figure S3A). Similarly, immuno-
precipitation of HA-LRP6 co-purified endogenous AAK1, and
reciprocally, immunopurification of overexpressed FLAG-AAK1
revealed co-complexed endogenous LRP6 (Figures S3B and
S3C, respectively). Finally, immunoprecipitation of endogenous
AAK1 showed co-complexed endogenously expressed LRP6
(Figure S3D). Interestingly, WNT3A stimulation suppressed the
association of LRP6 and AAK1 in all experiments (Figures
S3A–S3D). Because the AP2 complex is known to associate
with LRP6 (Kim et al., 2013), we next tested if AP2M1 was
required for the AAK1-LRP6 interaction. Co-overexpression of
AAK1 constructs (WT, 74A, and dAID) and HA-LRP6 followed
by FLAG affinity purification and western blot analysis demon-
strated that the AAK1 AP2 binding domain is required for the
AAK1-LRP6 interaction (Figure S3E).
AAK1 silencing potentiated WNT3A-driven b-catenin activa-
tion and increased LRP6 protein levels in whole cell lysate and
on the membrane (Figures 5B, 5C, and 5E). Because cargo tar-
geted by CME can be directed to lysosomes for degradation,
we tested if the decreased LRP6 levels we observed following
AAK1 overexpression were due to CME of LRP6 and subsequent
lysosomal degradation. AAK1 was overexpressed in HEK293T
cells before treatment with bafilomycin A1, an inhibitor of lyso-
somal acidification. Western blot analysis established that bafi-
lomycin A1 treatment rescued AAK1-driven downregulation of
LRP6 (Figure 5G). Together, these results suggest that AAK1 in-
hibits WNT signaling by inducing CME endocytosis and lyso-
somal degradation of LRP6.
WNT3A Induces AAK1 Phosphorylation of AP2M1
Within 15–30min of WNT3A treatment, LRP6 is phosphorylated
by GSK3b and CK1g (casein kinase 1g), resulting in transient
suppression of b-catenin phosphorylation and degradation
(Hernández et al., 2012; Liu et al., 1999, 2002; Zeng et al.,
2005). Extended duration of WNT3A stimulation of 4–6 hr re-
sults in MVB formation and sequestration of GSK3b (Taelman
et al., 2010). Here we asked if WNT3A treatment regulated
AAK1-dependent phosphorylation of AP2M1. Time-course
analysis in HT1080 or HEK293T cells revealed WNT3A-induced
phosphorylation of AP2M1 at 8–10 hr post-treatment, with no
change in total AP2M1 or AAK1 protein levels (Figure 6A). To
rule out artifacts due to the use of WNT3A CM and to extend
relevance to a second cell type, we treated HT1080 cells
(Figure S4A) and HEK293T (Figure S4B) cells with recombinant
humanWNT3A (rhWNT3A) over a time course of 4–16 hr. West-
ern blot analysis revealed an increase in pAP2M1 protein levels
8–10 hr post-WNT3A stimulation. We also tested the impor-
tance of continued exposure to WNT ligand over the time
course compared with transient pulse of WNT3A. Here, cells
were treated with WNT3A for 15 min before replacement with
fresh media (Figures S4C and S4D). These experiments
demonstrated that a pulse of WNT3A induced a similar increase
in AP2M1 phosphorylation compared with continuous expo-
sure to WNT3A ligand.
The WNT3A-induced phosphorylation of AP2M1 required
AAK1 expression and activity. First, HT1080 cells or HEK293T
cells were treated with WNT3A CM and the AAK1 inhibitor 25A
before western blot analysis of phosphorylated AP2M1; 25A
blocked WNT3A-induced phosphorylation of AP2M1 (Figures
S4C and S4D). Additionally, the AAK1 inhibitor blocked
WNT3A-induced AP2M1 phosphorylation when added at any
time point following WNT3A treatment (Figure S4E). Second,
siRNA silencing of AAK1 also suppressed WNT3A-induced
phosphorylation of AP2M1 (Figure 6B). These data suggest
that at 8–10 hr post-WNT3A treatment, AAK1-dependent phos-
phorylation of AP2M1 increases to form a negative feedback
loop of CME of LRP6 to decrease its abundance on the plasma
membrane.Intrigued with the delayed WNT3A-induced phosphorylation
of AP2M1 by AAK1, we performed a series of functional assays
to identify requisite signaling events. First, we found that AAK1-
mediated pAP2M1 accumulation was induced by rhWNT3A (3A)
and rhWNT5A (5A), the latter of which signals in a b-catenin-in-
dependent fashion (Figure 6C). Second, inhibition of GSK3b
with CHIR99021 did not result in elevated pAP2M1 levels, sug-
gesting that WNT3A-induced pAP2M1 did not require b-cate-
nin-dependent transcription (Figure 6D). In agreement with these
data, inhibiting b-catenin-dependent transcription with overex-
pressed dominant-negative TCF7L2/TCF4 (dnTCF7L2/dnTCF4)
did not affect pAP2M1 increase (Figure 6E). Third, using
HEK293T cells lacking all three DVL proteins via CRISPR-Cas9
triple-knockout (TKO) cells (clones 4 and 6) (Gammons et al.,
2016b) and HEK293T LRP5/6 CRISPR-Cas9 double-knockout
(DKO) cells, we tested whether WNT3A promoted phosphoryla-
tion of AP2M1 (Figure 6F). In the absence of LRP5/6 or DVL,
AP2M1 phosphorylation did not increase following WNT treat-
ment. Interestingly, background pAP2M1 levels are increased
in both LRP5/6 DKO and DVL TKO cells compared with WT
HEK293T cells (Figure 6F). Fourth, previous studies established
that PIP2 levels increase following short-term (4 hr) WNT3A
treatment and that PIP2 is required for WNT signalosome
formation (Kim et al., 2013; Pan et al., 2008). Furthermore,
PIP2 recruits AP2 to the signalosome, leading to CME of LRP6
(Kim et al., 2013). Thus, we hypothesized that PIP2 is required
for WNT3A-induced phosphorylation of AP2M1 by AAK1. To
test this hypothesis, we inhibited PIP2 by treating cells with
neomycin or carbachol, both of which block PIP2 signaling
(Baron et al., 1993; Huang et al., 1999). Treatment of HT1080
cells with neomycin or carbachol blocked WNT3A-induced
phosphorylation of AP2M1 (Figure 6G). Furthermore, we blocked
PIP2 production by silencing the PI4K2a kinase with two non-
overlapping siRNAs. PI4K2a phosphorylates phosphatidylinosi-
tol (PI) to phosphatidylinositol 4-phosphate (PI4P) and is required
for subsequent PIP2 production (Toker, 1998). In agreement with
the neomycin or carbachol experiments, PI4K2a silencing in
HT1080 cells blocked WNT3A-dependent increase in pAP2M1
(Figure 6H). We conclude that WNT ligands drive AAK1-depen-
dent phosphorylation of AP2M1 in amanner that is (1) temporally
delayed from signalosome formation, (2) independent of b-cate-
nin-mediated transcription, (3) dependent on LRP5/6 and DVL
protein expression, and (4) dependent on PIP2 production.
DISCUSSION
CME is a well-established regulator of WNT signaling, although
whether CME promotes or inhibits the WNT pathway remains
debated (Bilic et al., 2007; Blitzer and Nusse, 2006; Gammons
et al., 2016a; Kim et al., 2013; Pan et al., 2008; Taelman et al.,
2010; Yamamoto et al., 2008). Certainly, contextual and tempo-
ral features in CME-directed WNT studies are important. As a
central and positive regulator of CME, our discovery of AAK1
as a WNT modulator is no surprise. Collectively our data show
that AAK1 negatively regulates b-catenin-dependent WNT
signaling through CME endocytosis of LRP6. Although the
experiments have not yet been done, we speculate that FZD is
similarly targeted by AAK1 andCME. In the course of our studies,Cell Reports 26, 79–93, January 2, 2019 87
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Figure 6. WNT Treatment Induces AAK1-, PIP2-Dependent Phosphorylation of AP2M1
(A) Western blot analysis of HT1080 cells treated with WNT3A CM for indicated times.
(B) Western blot analysis of HT1080 cells transfected with either AAK1 or control siRNA for 72 hr. Cells were then treated with rhWNT3A (200 ng/mL) for 15 min,
then the medium was changed for fresh, complete DMEM, and cells were incubated for 9 hr.
(C) Western blot analysis of pAP2M1 levels in HEK293T cells treated with either rhWNT3A (3A) or rhWNT5A (5A) (200 ng/mL) for 9 hr. The box-and-whisker plot
represents pAP2M1/AP2M1 expression from four biological replicates quantified by LiCOR software.
(D) Western blot analysis of HT1080 cells treated with either CHIR99021 compound (1 mM) or rhWNT3A (200 ng/mL) for the indicated time.
(E) HEK293T cells were transfected with FLAG-dnTCF7L2 for 24 hr. Cells were then treated with WNT3A for 15 min, then the medium was changed for fresh,
complete DMEM, incubated for 9 hr, and analyzed using western blot.
(F) Western blot analysis of HEK293T WT, DVL TKO clone #4, DVL TKO clone #6, and LRP5/6 DKO cells treated with WNT3A CM for 9 hr.
(G) Western blot analysis of HT1080 cells treated with WNT3A CM for 15 mins, then the medium was changed for complete DMEM containing either carbachol
(50 mM) or neomycin (100 mM). Cells were incubated for 9 hr prior to cell harvest.
(H) Western blot analysis of HT1080 cells transfected with siRNA against PI4K2a for 72 hr and pulsed with WNT3A CM for 15 mins and then incubated for 9 hr.
All panels are representative of biological triplicates, unless otherwise noted. For complete statistics, see STAR Methods.
See also Figure S4.we discovered an unexpected WNT-induced phosphorylation
event on T156 of AP2M1. This wasmediated by AAK1 and repro-
ducibly occurred at 8–10 hr post-WNT treatment. In Figure 7, we
summarize our findings in a multi-step model that integrates
WNT-driven signalosome formation, PIP2 production, AAK1,
AP2M1 phosphorylation, and CME of LRP6.
In the absence of WNT ligand, FZD and LRP6 remain dissoci-
ated, allowing b-catenin phosphorylation, ubiquitylation, and
degradation (Liu et al., 1999; Liu et al., 2002). Within minutes of
WNT stimulation, the WNT signalosome forms, resulting in tran-
sient repression of b-catenin phosphorylation by GSK3b (Fig-
ure 7A) (Bilic et al., 2007). A key step in signalosome formation
is recruitment of the signalosome to nascent clathrin-coated
pits with high local concentrations of DVL, which allows the88 Cell Reports 26, 79–93, January 2, 2019dimerization of DVL, thus potentiating WNT signaling (Gammons
et al., 2016a). The newly formedWNT signalosome requires PIP2
for assembly and contains both clathrin and AP2 (Figure 7A) (Pan
et al., 2008). On the basis of our data, we suggest that long-term
(8–10 hr) WNT stimulation induces a spike in AAK1-dependent
phosphorylation of T156-AP2M1. This promotes clathrin poly-
merization, clathrin-coated pit stabilization and ultimately CME
of LRP6, thus constituting a WNT-driven and AAK1-dependent
negative feedback loop.
Central to our model is the increase in phosphorylated AP2M1
levels at 8–10 hr post-WNT treatment. Phosphoinositide is con-
verted to PIP2 by PI4K2a and PIP5K (Toker, 1998). Importantly,
PIP5K1 association with the DIX domain of DVL1/2/3 results in
activation of PIP5K1 (Hu et al., 2015; Pan et al., 2008). One
Figure 7. Proposed Model for AAK1-Dependent and CME of LRP6
(A) Within minutes of WNT ligand exposure, FZD and LRP5/6 co-complex, allowing formation of the LRP6 signalosome in nascent clathrin-coated pits. Sig-
nalosome formation requires DVL domain swapping and polymerization, as well as PIP2 and AP2 recruitment. This promotes accumulation of b-catenin and
activation of the WNT signaling pathway.
(B) Prolonged exposure to WNT ligand drives AAK1-dependent AP2M1 phosphorylation, CME, and ultimately removal of the WNT receptors from the plasma
membrane.hypothesis is that through this mechanism, WNT-driven recruit-
ment of DVL to the LRP/FZD receptor complex results in a time-
dependent increase in local PIP2 production. PIP2 and cargo
proteins allosterically activate the AP2 complex, thus driving
clathrin polymerization and maturation of clathrin-coated pits
(Höning et al., 2005; Kadlecova et al., 2017). Phosphorylation
of AP2M1 by AAK1 stabilizes the AP2 complex in an open/active
confirmation, promoting the binding of clathrin and cargo
proteins and ultimately enhancing CME (Figure 7B) (Conner
et al., 2003). Although we do not yet understand the mechanistic
details, we speculate that PIP2 levels continue to rise hours after
WNT stimulation, possibly triggering an increase in AAK1-
dependent phosphorylation of AP2M1 and CME of LRP6 (Fig-
ure 7B). Further studies that quantify PIP2 levels at 8–10 hr
post-WNT stimulation are needed.
Alternatively, the AP2 complex has been reported to cycle be-
tween phosphorylated and dephosphorylated states during
CME and that this cycling is necessary for robust CME (Kadle-
cova et al., 2017). Therefore, it is possible that WNT stimulation
shifts the AAK1/phosphatase balance to favor phosphorylated
AP2M1. Another possibility is AAK1 itself is phosphorylated,
either via AAK1 autophosphorylation or phosphorylation by
another kinase, resulting in increased AAK1 activity, AP2M1
phosphorylation, and CME of LRP6. Interestingly, previous
studies demonstrated that GSK3b inhibition results in increased
dynamin-1 activity, leading to rapid and dysregulated CME (Lib-
erali et al., 2014; Reis et al., 2015). It is possible that GSK3b
sequestration within MVBs (Taelman et al., 2010) and increasedAAK1 activity both contribute toWNT-driven CME of LRP6. Last,
given the delayed nature of the AAK1-AP2M1 phospho-event,
we were surprised that b-catenin-dependent transcription was
not required. Indeed, we also show that the b-catenin-indepen-
dent WNT ligand WNT5A similarly induces pT156-AP2M1. Inter-
estingly, previous studies demonstrated that an interaction
between DVL2 and AP2 is required for WNT5A-induced FZD4
endocytosis (Yu et al., 2007). Together, these data suggest a
regulatory role for AAK1 in FZD endocytosis. Although not yet
validated in vivo, we hypothesize that in certain developmental
or disease contexts, WNT-induced pT156-AP2M1may establish
a negative feedback loop to remove LRP/FZD from the cell
membrane. Collectively, the molecular events suggested in this
time-delayed model are consistent with the timing reported in
the GSK3-sequestration model proposed by De Robertis and
colleagues (Taelman et al., 2010).
The AP2 complex binds Yxxɸ or dileucine motifs within the
intracellular domains of transmembrane cargo proteins (Chen
et al., 1990; Collawn et al., 1990). Through phosphorylation of
T156-AP2M1, AAK1 was previously shown to promote associa-
tion of the AP2 complex with cargo (Ricotta et al., 2002). Interest-
ingly, in co-immunoprecipitation experiments, we discovered
AP2 regulates the association between AAK1 and LRP6. AP2 in-
teracts with LRP6 through a conserved Yxxɸ motif, which is
required for WNT signalosome formation (Gammons et al.,
2016a; Kim et al., 2013). We also report that the AAK1-LRP6
co-complex dissipates following WNT3A treatment. Although
further experimentation is needed to define the dynamics ofCell Reports 26, 79–93, January 2, 2019 89
protein-protein interactions during signalosome formation and
CME, it is possible that following AAK1-dependent phosphoryla-
tion of AP2M1, AAK1 dissociates from the LRP6/AP2 complex.
AAK1 contributes to several neurological disorders, including
neuropathic pain, Alzheimer’s disease, Parkinson’s disease,
schizophrenia, and amyotrophic lateral sclerosis (Kostich et al.,
2016; Shi et al., 2014). AAK1 has a described role in dendrite
branching and spine development (Ultanir et al., 2012), and
through the regulation of Neuregulin1/ErbB4, AAK1 has been
linked to schizophrenia (Kuai et al., 2011). Just recently, the
LX9211 AAK1 inhibitor passed phase 1 clinical trials for
neuropathic pain. Here we report the development of a potent
and selective AAK1 pharmacological inhibitor (SGC-AAK1-1).
SGC-AAK1-1 demonstrates improved biochemical selectivity
over the phase 1 clinical agent LX9211 and is confirmed to be
cell active. Thus, we report the best available chemical tool to
study AAK1/BMP2K pathways and related biology. Like the
lead compound 25A, SGC-AAK1-1 inhibited AAK1-dependent
phosphorylation of AP2M1 and activated WNT signaling. Look-
ing forward, in vitro and in vivo neural-directed studies of SGC-
AAK1-1 and its comparison with LX9211 are needed to evaluate
the therapeutic potential of SGC-AAK1-1. Furthermore, while we
describe a role for AAK1 in negatively regulating WNT signaling,
AAK1 also inhibits Neuregulin1/ErbB4 and positively regulates
the NOTCH pathway (Gupta-Rossi et al., 2011; Kuai et al.,
2011). Therefore, AAK1 inhibitors may also regulate these
signaling cascades and consequently prove therapeutically
beneficial in diseases with misregulated NOTCH or Neuregu-
lin1/ErbB4 signaling. In cancer, mutation and altered expression
of several genes promote WNT receptor stability on the plasma
membrane, resulting in hyperactive WNT signaling and tumori-
genesis (e.g., ZNRF3/RNF43 and USP6; Hao et al., 2012; Koo
et al., 2012; Madan et al., 2016; Ruffner et al., 2012; Schmid,
2017). Whether AAK1 expression or activity is suppressed in
cancer and if this contributes to WNT activation remain to be
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Robinson, M., Robinson, C., Haucke, V., and Owen, D.J. (2005). Phosphatidy-
linositol-(4,5)-bisphosphate regulates sorting signal recognition by the
clathrin-associated adaptor complex AP2. Mol. Cell 18, 519–531.
Hu, J., Yuan, Q., Kang, X., Qin, Y., Li, L., Ha, Y., and Wu, D. (2015). Resolution
of structure of PIP5K1A reveals molecular mechanism for its regulation by
dimerization and dishevelled. Nat. Commun. 6, 8205.
Huang, Y., Qureshi, I.A., and Chen, H. (1999). Effects of phosphatidylinositol
4,5-bisphosphate and neomycin on phospholipase D: kinetic studies. Mol.
Cell. Biochem. 197, 195–201.
Jiang, Y., He, X., and Howe, P.H. (2012). Disabled-2 (Dab2) inhibits Wnt/b-cat-
enin signalling by binding LRP6 and promoting its internalization through
clathrin. EMBO J. 31, 2336–2349.
Johannessen, C.M., Boehm, J.S., Kim, S.Y., Thomas, S.R., Wardwell, L.,
Johnson, L.A., Emery, C.M., Stransky, N., Cogdill, A.P., Barretina, J., et al.
(2010). COT drives resistance to RAF inhibition through MAP kinase pathway
reactivation. Nature 16, 968–972.
Kabsch, W. (2010). Xds. Acta Crystallogr. D Biol. Crystallogr. 66, 125–132.
Kadlecova, Z., Spielman, S.J., Loerke, D., Mohanakrishnan, A., Reed, D.K.,
and Schmid, S.L. (2017). Regulation of clathrin-mediated endocytosis by hier-
archical allosteric activation of AP2. J. Cell Biol. 216, 167–179.
Keller, S., Vargas, C., Zhao, H., Piszczek, G., Brautigam, C.A., and Schuck, P.
(2012). High-precision isothermal titration calorimetry with automated peak-
shape analysis. Anal. Chem. 84, 5066–5073.
Kim, I., Pan,W., Jones, S.A., Zhang, Y., Zhuang, X., andWu, D. (2013). Clathrin
and AP2 are required for PtdIns(4,5)P2-mediated formation of LRP6 signalo-
somes. J. Cell Biol. 200, 419–428.
Koo, B.K., Spit, M., Jordens, I., Low, T.Y., Stange, D.E., van de Wetering, M.,
van Es, J.H., Mohammed, S., Heck, A.J., Maurice, M.M., and Clevers, H.
(2012). Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endo-
cytosis of Wnt receptors. Nature 488, 665–669.
Kostich, W., Hamman, B.D., Li, Y.W., Naidu, S., Dandapani, K., Feng, J.,
Easton, A., Bourin, C., Baker, K., Allen, J., et al. (2016). Inhibition of AAK1
kinase as a novel therapeutic approach to treat neuropathic pain.
J. Pharmacol. Exp. Ther. 358, 371–386.
Kuai, L., Ong, S.E., Madison, J.M., Wang, X., Duvall, J.R., Lewis, T.A., Luce,
C.J., Conner, S.D., Pearlman, D.A., Wood, J.L., et al. (2011). AAK1 identified
as an inhibitor of neuregulin-1/ErbB4-dependent neurotrophic factor signaling
using integrative chemical genomics and proteomics. Chem. Biol. 18,
891–906.
Lebensohn, A.M., Dubey, R., Neitzel, L.R., Tacchelly-Benites, O., Yang, E.,
Marceau, C.D., Davis, E.M., Patel, B.B., Bahrami-Nejad, Z., Travaglini, K.J.,
et al. (2016). Comparative genetic screens in human cells reveal new regulato-
ry mechanisms in WNT signaling. eLife 5, e21459.
Liberali, P., Snijder, B., and Pelkmans, L. (2014). A hierarchical map of regula-
tory genetic interactions in membrane trafficking. Cell 157, 1473–1487.
Liu, C., Kato, Y., Zhang, Z., Do, V.M., Yankner, B.A., and He, X. (1999). beta-
Trcp couples beta-catenin phosphorylation-degradation and regulates Xeno-
pus axis formation. Proc. Natl. Acad. Sci. U S A 96, 6273–6278.
Liu, C., Li, Y., Semenov,M., Han, C., Baeg, G.H., Tan, Y., Zhang, Z., Lin, X., and
He, X. (2002). Control of beta-catenin phosphorylation/degradation by a dual-
kinase mechanism. Cell 108, 837–847.
Liu, C.C., Kanekiyo, T., Roth, B., and Bu, G. (2014). Tyrosine-based signal me-
diates LRP6 receptor endocytosis and desensitization of Wnt/b-catenin
pathway signaling. J. Biol. Chem. 289, 27562–27570.
Madan, B.,Walker,M.P., Young, R., Quick, L., Orgel, K.A., Ryan,M., Gupta, P.,
Henrich, I.C., Ferrer, M., Marine, S., et al. (2016). USP6 oncogene promotes
Wnt signaling by deubiquitylating Frizzleds. Proc. Natl. Acad. Sci. U S A 113,
E2945–E2954.
Mao, J., Wang, J., Liu, B., Pan, W., Farr, G.H., 3rd, Flynn, C., Yuan, H., Takada,
S., Kimelman, D., Li, L., and Wu, D. (2001). Low-density lipoprotein receptor-92 Cell Reports 26, 79–93, January 2, 2019related protein-5 binds to Axin and regulates the canonical Wnt signaling
pathway. Mol. Cell 7, 801–809.
McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L.C.,
and Read, R.J. (2007). Phaser crystallographic software. J. Appl. Cryst. 40,
658–674.
Metcalfe, C., Mendoza-Topaz, C., Mieszczanek, J., and Bienz, M. (2010). Sta-
bility elements in the LRP6 cytoplasmic tail confer efficient signalling upon DIX-
dependent polymerization. J. Cell Sci. 123, 1588–1599.
Nusse, R., and Clevers, H. (2017). Wnt/b-catenin signaling, disease, and
emerging therapeutic modalities. Cell 169, 985–999.
Pan,W., Choi, S.C., Wang, H., Qin, Y., Volpicelli-Daley, L., Swan, L., Lucast, L.,
Khoo, C., Zhang, X., Li, L., et al. (2008). Wnt3a-mediated formation of phos-
phatidylinositol 4,5-bisphosphate regulates LRP6 phosphorylation. Science
321, 1350–1353.
Phonphok, Y., and Rosenthal, K.S. (1991). Stabilization of clathrin coated ves-
icles by amantadine, tromantadine and other hydrophobic amines. FEBS Lett.
281, 188–190.
Reis, C.R., Chen, P.H., Srinivasan, S., Aguet, F., Mettlen, M., and Schmid, S.L.
(2015). Crosstalk between Akt/GSK3b signaling and dynamin-1 regulates cla-
thrin-mediated endocytosis. EMBO J. 34, 2132–2146.
Ricotta, D., Conner, S.D., Schmid, S.L., von Figura, K., and Honing, S. (2002).
Phosphorylation of the AP2 mu subunit by AAK1mediates high affinity binding
to membrane protein sorting signals. J. Cell Biol. 156, 791–795.
Robers, M.B., Dart, M.L., Woodroofe, C.C., Zimprich, C.A., Kirkland, T.A., Ma-
chleidt, T., Kupcho, K.R., Levin, S., Hartnett, J.R., Zimmerman, K., et al. (2015).
Target engagement and drug residence time can be observed in living cells
with BRET. Nat. Commun. 6, 10091.
Ruffner, H., Sprunger, J., Charlat, O., Leighton-Davies, J., Grosshans, B., Sal-
athe, A., Zietzling, S., Beck, V., Therier, M., Isken, A., et al. (2012). R-Spondin
potentiates Wnt/b-catenin signaling through orphan receptors LGR4 and
LGR5. PLoS ONE 7, e40976.
Schmid, S.L. (2017). Reciprocal regulation of signaling and endocytosis: Impli-
cations for the evolving cancer cell. J. Cell Biol. 216, 2623–2632.
Shi, B., Conner, S.D., and Liu, J. (2014). Dysfunction of endocytic kinase AAK1
in ALS. Int. J. Mol. Sci. 15, 22918–22932.
Song, B.D., Yarar, D., and Schmid, S.L. (2004). An assembly-incompetent
mutant establishes a requirement for dynamin self-assembly in clathrin-medi-
ated endocytosis in vivo. Mol. Biol. Cell 15, 2243–2252.
Sorrell, F.J., Szklarz, M., Abdul Azeez, K.R., Elkins, J.M., and Knapp, S. (2016).
Family-wide structural analysis of human Numb-associated protein kinases.
Structure 24, 401–411.
Taelman, V.F., Dobrowolski, R., Plouhinec, J.L., Fuentealba, L.C., Vorwald,
P.P., Gumper, I., Sabatini, D.D., and De Robertis, E.M. (2010). Wnt signaling
requires sequestration of glycogen synthase kinase 3 inside multivesicular en-
dosomes. Cell 143, 1136–1148.
Tamai, K., Semenov, M., Kato, Y., Spokony, R., Liu, C., Katsuyama, Y., Hess,
F., Saint-Jeannet, J.P., andHe, X. (2000). LDL-receptor-related proteins inWnt
signal transduction. Nature 407, 530–535.
Toker, A. (1998). The synthesis and cellular roles of phosphatidylinositol 4,5-bi-
sphosphate. Curr. Opin. Cell Biol. 10, 254–261.
Ultanir, S.K., Hertz, N.T., Li, G., Ge, W.P., Burlingame, A.L., Pleasure, S.J.,
Shokat, K.M., Jan, L.Y., and Jan, Y.N. (2012). Chemical genetic identification
of NDR1/2 kinase substrates AAK1 and Rabin8 Uncovers their roles in dendrite
arborization and spine development. Neuron 73, 1127–1142.
Vasta, J.D., Corona, C.R., Wilkinson, J., Zimprich, C.A., Hartnett, J.R., Ingold,
M.R., Zimmerman, K., Machleidt, T., Kirkland, T.A., Huwiler, K.G., et al. (2018).
Quantitative, wide-spectrum kinase profiling in live cells for assessing the ef-
fect of cellular ATP on target engagement. Cell Chem. Biol. 25, 206–214.
Walker, M.P., Stopford, C.M., Cederlund, M., Fang, F., Jahn, C., Rabinowitz,
A.D., Goldfarb, D., Graham, D.M., Yan, F., Deal, A.M., et al. (2015). FOXP1 po-
tentiates Wnt/b-catenin signaling in diffuse large B cell lymphoma. Sci. Signal.
8, ra12.
Wang, L.H., Rothberg, K.G., and Anderson, R.G. (1993). Mis-assembly of
clathrin lattices on endosomes reveals a regulatory switch for coated pit
formation. J. Cell Biol. 123, 1107–1117.
Winn, M.D., Ballard, C.C., Cowtan, K.D., Dodson, E.J., Emsley, P., Evans,
P.R., Keegan, R.M., Krissinel, E.B., Leslie, A.G., McCoy, A., et al. (2011). Over-
view of the CCP4 suite and current developments. Acta Crystallogr. D Biol.
Crystallogr. 67, 235–242.
Yamamoto, H., Sakane, H., Yamamoto, H., Michiue, T., and Kikuchi, A. (2008).
Wnt3a and Dkk1 regulate distinct internalization pathways of LRP6 to tune the
activation of beta-catenin signaling. Dev. Cell 15, 37–48.
Yang, X., Boehm, J.S., Yang, X., Salehi-Ashtiani, K., Hao, T., Shen, Y., Lu-
bonja, R., Thomas, S.R., Alkan, O., Bhimdi, T., et al. (2011). ). A publicgenome-scale lentiviral expression library of human ORFs. Nat. Methods 8,
659–661.
Yu, A., Rual, J.F., Tamai, K., Harada, Y., Vidal, M., He, X., and Kirchhausen,
T. (2007). Association of Dishevelled with the clathrin AP-2 adaptor is
required for Frizzled endocytosis and planar cell polarity signaling. Dev.
Cell 12, 129–141.
Zeng, X., Tamai, K., Doble, B., Li, S., Huang, H., Habas, R., Okamura, H.,
Woodgett, J., and He, X. (2005). A dual-kinasemechanism forWnt co-receptor
phosphorylation and activation. Nature 438, 873–877.
Zhao, H., Piszczek, G., and Schuck, P. (2015). SEDPHAT—a platform for
global ITC analysis and global multi-method analysis of molecular interactions.
Methods 76, 137–148.Cell Reports 26, 79–93, January 2, 2019 93
STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Rabbit polyclonal anti-AAK1 Bethyl Labs Cat#A302-146A; RRID:AB_1720315
Rabbit monoclonal anti-Clathrin Heavy Chain (D3C6) XP Cell Signaling Technology Cat#4796S; RRID:AB_10557412
Rabbit monoclonal anti-LRP6 Cell Signaling Technology Cat#3395; RRID:AB_1950408
Rabbit polyclonal anti-phospho-LRP6 (S1490) Cell Signaling Technology Cat#2568; RRID:AB_2139327
Rabbit polyclonal Anti-Human AP2M1, phospho (Thr156) Cell Signaling Technology Cat#3843S; RRID:AB_2056358
Rabbit monoclonal anti-PIP4K2A (D83C1) Cell Signaling Technology Cat#5527; RRID:AB_2722636
Rabbit polyclonal anti-Phospho-beta-Catenin (Ser33/37/Thr41) Cell Signaling Technology Cat#9561S; RRID:AB_331729
Monoclonal mouse ANTI-FLAG M2 Sigma-Aldrich Cat#F3165; RRID:AB_259529
Rat monoclonal Anti-HA High Affinity (clone 3F10) Roche Cat#11867423001; RRID:AB_390918
Monoclonal mouse anti-beta-Tubulin Sigma-Aldrich Cat# T8328; RRID:AB_1844090
Mouse monoclonal anti-LRP6 Abcam Cat# ab75358; RRID:AB_2139308
Rabbit monoclonal anti-AP2M1 (phospho T156) [EPR4700] Abcam Cat# ab109397; RRID:AB_10866362
Rabbit monoclonal anti-AP2M1 [EP2695Y] Abcam Cat# ab75995; RRID:AB_1309955
Mouse monoclonal anti-CTNNB1 BD Biosciences Cat#163510
Mouse monoclonal anti-GSK-3 beta BD Biosciences Cat#610201; RRID:AB_397600
Mouse monoclonal anti-Dvl-3 Santa Cruz Biotechnology Cat# sc-8027; RRID:AB_627434
Mouse monoclonal beta-actin Santa Cruz Biotechnology Cat# sc-47778 HRP; RRID:AB_2714189
Rabbit polyclonal AP2M1 Thermo Fisher Scientific Cat# PA5-21360; RRID:AB_11154082
IRDye 800CW Goat anti Mouse IgG LI-COR Biosciences Cat# P/N 925-32210; RRID:AB_2687825
IRDye 680LT Goat anti Mouse IgG LI-COR Biosciences Cat#P/N 925-68020; RRID:AB_2687826
IRDye800CW Goat anti Rabbit IgG LI-COR Biosciences Cat#925-32211; RRID:AB_2651127
IRDye 680LT Goat anti Rabbit IgG LI-COR Biosciences Cat#P/N 925-68021; RRID:AB_2713919
Mouse monoclonal anti-LRP6 (Clone 255302) R and D Systems Cat# MAB1505; RRID:AB_10889810
Monoclonal mouse IgG2A Isotype Control (Clone 20102) R and D Systems Cat# MAB003; RRID:AB_357345
R-Phycoerythrin-AffiniPure F(ab’)2 Fragment Goat
Anti-Mouse IgG
Jackson Immunoresearch Cat#115-116-146; RRID:AB_2338629
Polyclonal rabbit anti-GFP Abcam Cat# ab290; RRID:AB_303395
Bacterial and Virus Strains
BL21(DE3) for recombinant protein expression Laboratory of
Dr. Opher Gileadi
N/A
Chemicals, Peptides, and Recombinant Proteins
CHIR99021 Cayman Chemicals Cat#13122 ; Cas#252917-06-9
Chlorpromazine HCL Sigma-Aldrich Cat#C0982 ; Cas#69-09-0
Bafilomycin A1 Cayman Chemicals Cat#11038 ; Cas#88899-55-2
WNT3A PeproTech Cat#315-20
WNT5A R and D Systems Cat#645-WN-010
Neomycin trisulfate salt hydrate Sigma-Aldrich Cat#N6386 ; Cas#1405-10-3
Carbachol EMD Chemicals Cat#212385 ; Cas#51-83-2
Staurosporine Sigma-Aldrich Cat#S4400; Cas# 62996-74-1
NanoBRET Tracer K-5 Promega Cat# N248A
AP-2 derived peptide WatsonBio Custom (biotin-GGSQITSQVTGQIGWRR-
amide)
(Continued on next page)
e1 Cell Reports 26, 79–93.e1–e8, January 2, 2019
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Critical Commercial Assays
Pierce Cell Surface Protein Isolation Kit ThermoFisher Cat#89881
PureLink RNA Mini Kit Invitrogen Cat#12183018A
iScript cDNA Synthesis Kit BioRad Cat#1708891
Dual-Luciferase Reporter Assay System Promega Cat#E1910
Deposited Data










BMP2K KD bound to 25A This paper PDB ID: 5IKW ; https://www.rcsb.org/
structure/5IKW
Experimental Models: Cell Lines
Human male: HT1080 ATCC CCL-121
Human fetus: HEK293T/17 ATCC CRL-11268
Human: RKO ATCC CRL-2577
Mouse male: Lcells ATCC CRL-2648
Mouse male: WNT3A expressing Lcells ATCC CRL-2647
Oligonucleotides
See Table S7 for complete list N/A
Recombinant DNA
Human kinase open reading frame library Yang et al., 2011 ;
Johannessen et al., 2010
Addgene #1000000014
Flag-AAK1-WT Dr. Sean Conner Conner et al., 2003
Flag-AAK1-dAID Dr. Sean Conner Conner et al., 2003
Flag-AAK1-74A Dr. Sean Conner Conner et al., 2003
GFP-LRP6 Dr. Randell Moon This paper
HA-LRP6 Dr. Randell Moon This paper
ANKRD6 Dr. Randell Moon This paper
FLAG-dnTCF7L2 Dr. Randell Moon Walker et al., 2015.
TK-Renilla Dr. Randell Moon Walker et al., 2015.
BAR-reporter Dr. Randell Moon Walker et al., 2015.
NFkB-reporter Walker et al., 2015.
TGFb-reporter Walker et al., 2015.
ADCK1 Yang et al., 2011 ;
Johannessen et al., 2010
Addgene #1000000014
ADCK2 Yang et al., 2011 ;
Johannessen et al., 2010
Addgene #1000000014
MAST1 Yang et al., 2011 ;
Johannessen et al., 2010
Addgene #1000000014
TGFBR3 Yang et al., 2011 ;
Johannessen et al., 2010
Addgene #1000000014
K44A Dynamin 1 pEGFP Song et al., 2004 Addgene #34681
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Streptavidin beads GE Healthcare Cat#17-5113-01
Protein A/G Agarose ThermoFisher Cat#20421
EZview Red Flag M2 Affinity Gel Sigma-Aldrich Cat#F2426
EZview Red Anti-HA Affinity Gel Sigma-Aldrich Cat#E6779
NuPAGE 4-12% Bis-Tris Protein Gels ThermoFisher Cat#NP0321BOX
Nitrocellulose Membrane ThermoFisher Cat#88018
TansIT2020 Mirus Bio Cat#MIR5405
RNAiMAX Life technologies Cat#13778030
Fast SYBER Green Master Mix Applied Biosystems Cat#4385612
NanoLuc-AAK1 fusion vector Promega Cat#NV1001
NanoLuc-BMP2K fusion vector Promega Cat#NV1091CONTACT AND REAGENT RESOURCE SHARING
Further information and requests for resources and reagents should be directed to andwill be fulfilled by the LeadContact,Michael B.
Major (ben_major@email.unc.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines and tissue culture
All cells were cultured at 37C and 5% CO2. HT1080 (human male), HEK293T/17 (human fetus), RKO (human, gender N/A), Lcells
(mouse male), andWNT3A expressing Lcells (mouse male) were obtained from American Type Culture Collection (ATCC, Manassas,
VA) and grown in DMEM with 10% FBS. Each cell line was tested for mycoplasma contamination and passaged no more than 20
passages from the original ATCC stock. Cells were treated at the indicated concentrations with the following compounds:
CHIR99021 (Cayman Chemicals, Ann Arbor, MI), chlorpromazine HCL (Sigma-Aldrich, St. Louis, MO), bafilomycin A1 (Cayman
Chemicals), rhWNT3A (PeproTech, Rocky Hill, NJ), rhWNT5A (R&D, Minneapolis, MN), neomycin trisulfate salt hydrate (Sigma-Al-
drich) and carbachol (EMD Chemicals, Gibbstown, NJ).
METHOD DETAILS
WNT3A conditioned media
Conditioned media was collected as described by ATCC. Briefly, WNT3A and control Lcells were grown to 100% confluency before
fresh media was added, conditioned for 48 hr, and then collected.
Immunoprecipitation and immunoblotting
Immunoprecipitation (IP) experiments were performed as previously described (Jiang et al., 2012). Briefly, cells were lysed in 1%
Triton lysis buffer, passed through an 18 gauge needle, and cleared via centrifugation at max speed for 10 mins. For endogenous
IP experiments, antibody was conjugated to activated Protein A/G beads (ThermoFisher) for 1 hr at 4C with nutation. Conjugated
beads were then added to cleared lysate and incubated for 4 hr at 4C with nutation. For overexpression IP experiments, activated
Flag (Sigma-Aldrich) or HA (Sigma-Aldrich) beads were added directly to the cleared lysate and incubated for 1 hr at 4C with nuta-
tion. Following incubation, beads were washed 5 times with lysis buffer, then the sample was eluted at 95C for 5 mins, and a W.blot
was performed. Standard W.blotting techniques were utilized. Briefly, samples were run on a NuPAGE 4%–12% Bis-Tris Protein
Gel (ThermoFisher), then transferred to a nitrocellulose membrane. The membrane was then blocked and incubated overnight
with primary antibody at 4C with rotation, washed with TBST, incubated with secondary antibody, washed with TBST and imaged.e3 Cell Reports 26, 79–93.e1–e8, January 2, 2019
All images were obtained using a LiCOROdyssey imager and quantified with LiCOR software. For W.blot analysis, all antibodies were
used at a concentration of 1:1000,with the exception of loading controls, whichwere used at 1:10,000. Bethyl Labs (Montgomery, TX) –
AAK1 (A302-146a); Cell Signaling (Danvers,MA) –Clathrin (4796), LRP6 (3395), phospho-LRP6 (S1490) (2568), phospho-AP2M1 (T156)
(7399S), PIP4K2A (5527), phospho-CTNNB1 (S33/37/T41) (9561S); Sigma-Aldrich – FLAG M2 (F3165), HA (11867423001), and beta-
tubulin (T8328); Abcam (Cambridge, UK) – LRP6 (ab75358), AP2M1 (ab7995), p-AP2M1 (Thr156) (ab109397); BD Biosciences (San
Jose, CA) – CTNNB1 (610153), GSK3b (610201); Santa Cruz (Dallas, TX) – DVL3 (sc-8027), beta-actin (sc-47778); Invitrogen (Carlsbad,
CA) - AP2M1 (PA5-21360). Secondary antibodies were used at 1:5000 dilution and purchased from LiCOR Biosciences. Specific an-
tibodies used are as follows: IRDye 800CW Goat anti Mouse IgG (925-32210), IRDye 680LT Goat anti Mouse IgG (925-68020),
IRDye800CW Goat anti Rabbit IgG (925-32211), and IRDye 680LT Goat anti Rabbit IgG (925-68021).
Surface staining of LRP6
HEK293T cell were transfected for 48 hr prior to splitting into 60 cm plates with 400,000 cells/plate and allowed to attach overnight.
Cells were disassociated with 0.5 mM EDTA in DPBS and washed with FACS Buffer (2% FBS in DPBS). Cells were stained in FACS
buffer for 1 hour at on ice using 5 mg/mL LRP6 antibody (R&D) or Isotype Control (R&D) and secondary staining with 1:100 anti-mouse
PE (Jackson Immunoresearch,West Grove, PA) for 45mins. After staining, cells were fixedwith 2%paraformaldehyde in FACS buffer
and analyzed by the UNC-Flow Cytometry Core.
DNA constructs and siRNAs
The human kinase open reading frame library was obtained from Addgene (cat# 1000000014) and cloned into a custom
pHAGE-CMV-FLAG vector using Gateway cloning technology. All constructs were N-terminally sequence verified. Gain-of-function
kinome screen data is presented in Table S3 and has been deposited onMendeley Data (https://doi.org/10.17632/352fxh8r6t.1#file-
94081320-ab20-4178-8be2-233c7ea23b62). Wild-type AAK1 and mutants were a gift from Dr. Sean Conner (University of
Minnesota). GFP-LRP6, HA-LRP6, ANKRD6, and FLAG-dnTCF7L2 were kindly provided by Dr. Randell Moon (University of Wash-
ington). ADCK1, ADCK2,MAST1, and TGFBR3were obtained as part of the kinome library from Addgene. GFP-Dynamin1-K44Awas
obtained from Addgene. All siRNAs were obtained from Life Technologies (ThermoFisher, Waltham,MA), and sequences are listed in
Table S7.
Transcriptional reporter assays
All luciferase reporter assays and IncuCyte fluorescent reporter assays were performed as previously described (Walker et al., 2015).
Briefly, for loss-of-function assays, cell lines stably expressing the BAR-Firefly luciferase reporter and TK-Ren luciferase were
used and transfected with RNAiMAX (Life technologies, ThermoFisher) for 72 hr. For gain of function studies, the BAR-reporter
(20 ng), TK-Ren (10 ng), and indicated constructs (70 ng) were transfected with TansIT2020 (Mirus Bio) for 24 hr. For IncuCyte fluo-
rescent reporter assays, stable BAR-mCherry cells were treated and imaged as indicated using the IncuCyte Live Cell Analysis Sys-
tem from Essen BioScience. Luciferase readouts were normalized using co-transfected TK-Ren (Luciferase assays) and IncuCyte
Analysis was normalized to internal mCherry control. Conditions were plated in triplicate, and normalized values were averaged
across triplicates to yield the data presented and standard error. Each assay was repeated in biological triplicate, unless otherwise
stated. Firefly luciferase and the Renilla (Ren) control were detected using the Promega Dual-Luciferase Reporter Assay System per
the manufacturer’s protocol (Promega, Madison, WI). Plates were read on the EnSpire plate reader from PerkinElmer.
Real-Time Quantitative PCR
Quantitative PCR (qPCR) was performed as described previously (Walker et al., 2015). Briefly, cells were treated as indicated and
RNA was collected using PureLink RNA Mini Kit (Invitrogen, Carlsbad, CA). cDNA was generated from 1ug of RNA using the iScript
cDNA Synthesis Kit (BioRad, Hercules, CA) following kit specifications. qPCR was performed using Fast SYBER Green Master Mix
(Applied Biosystems, Foster City, CA) on the Applied Biosystems 7400HT followingmanufacturer specifications. Samples were run in
technical triplicate on a 384-well plate, with biological triplicates run on subsequent plates. Primers were previously published
(Walker et al., 2015) and sequences are listed in Table S7.
Generation of LRP5/6 DKO stable cell lines
HEK293T cells were transfected with Cas9 and sgRNAs targeting LRP5/6. Sequences are listed in Table S7. Deletions were
confirmed by immunoblotting and verified via sequencing.
Surface biotinylation
For surface biotinylation assays, the Pierce Cell Surface Protein Isolation Kit (ThermoFisher) was utilized and manufacturer specifi-
cations were followed. Briefly, cells were grown to 70% confluency, washed 3 times with cold PBS, and then biotinylated for 30 mins
at 4Cwith NHS-SS-sulfo-linked biotin (0.25mg/mL). The free biotin was quenched, and then the samples were washed 3 times with
cold TBS prior to lysis and sonication. Lysates were cleared and then incubated with Streptavidin beads (GE Healthcare, Little Chal-
font, UK) for 1 hour at 4C with nutation. Beads were washed 4 times with cold TBS and then proteins were eluted with LDS protein
loading buffer supplemented with DTT at 95C for 10 mins.Cell Reports 26, 79–93.e1–e8, January 2, 2019 e4
Chemistry general procedures
Reagents were purchased from commercial suppliers and used without further purification. 1H and 13C NMR spectra were collected
in methanol-d4 and recorded on Varian Inova 400 or Inova 500 spectrometers. Peak positions are given in parts per million (ppm)
downfield from tetramethylsilane as the internal standard; J values are expressed in hertz. Thin-layer chromatography (TLC) was per-
formed on silica gel F254 to evaluate reaction courses and mixtures. Flash chromatography was performed on Merck 60 silica gel
(0.063–0.200 mm). All non-aqueous reactions were performed under nitrogen atmosphere. Solutions containing the final products
were dried over Na2SO4 before filtration and concentration under reduced pressure using a rotary evaporator.
Crystal structure determination
Diffraction data were integrated using XDS (Kabsch, 2010) and scaled using AIMLESS from the CCP4 software suite (Winn et al.,
2011). Molecular replacement was performed with Phaser (McCoy et al., 2007) using BMP2K/AZD7762 (PDB: 4W9W) (Sorrell
et al., 2016) as a search model. Automated model building was performed with Buccaneer (Cowtan, 2006). Automated refinement
was performed in PHENIX (Adams et al., 2010). Coot (Emsley et al., 2010) was used for manual model building and real space refine-
ment. Structure validation was performed using MolProbity (Chen et al., 2010). Structure factors and coordinates have been depos-
ited in the PDB with code 5IKW.
Binding-displacement assays
The TR-FRET ligand binding-displacement assays for AAK1, BMP2K, GAK and STK16 were performed as previously described
(Asquith et al., 2018). Inhibitor binding was determined using a binding-displacement assay, which measures the ability of inhibitors
to displace a fluorescent tracer compound from the ATP binding site of the kinase domain. Inhibitors were dissolved in DMSO and
dispensed as 16-point, 2x serial dilutions in duplicate into black multi-well plates (Greiner). Each well contained either 0.5 nM or 1 nM
biotinylated kinase domain protein ligated to streptavidin-Tb-cryptate (Cisbio), 12.5 nM or 25 nM Kinase Tracer 236 (ThermoFisher
Scientific), 10 mM HEPES pH 7.5, 150 mM NaCl, 2 mM DTT, 0.01% BSA, 0.01% Tween-20. Final assay volume for each data point
was 5 mL, and final DMSO concentration was 1%. The kinase domain proteins were expressed in E. coli as a fusion with a C-terminal
AVI tag (vector pNIC-Bio3, NCBI reference JN792439) which was biotinylated by co-expressed BirA, and purified using the same
methods as used previously (Asquith et al., 2018). After setting up the assay plate it was incubated at room temperature for 1.5 hours
and then read using a TR-FRET proto Residue ranges were AAK1: 31-396, BMP2K: 38-345, GAK: 12-347, STK16: 13-305col on a
PheraStarFS plate reader (BMG Labtech). The data was normalized to 0% and 100% inhibition control values and fitted to a four
parameter dose-response binding curve in GraphPad Software (version 7, La Jolla, CA, USA). The determined IC50 values were con-
verted to Ki values using the Cheng-Prusoff equation and the concentration and KD values for the tracer (previously determined).
Kinome screening
The KINOMEscan assay panel was measured at DiscoverX Corporation as previously described (Davis et al., 2011). Data
collection can be found in Table S2 and has been deposited on Mendeley Data (https://doi.org/10.17632/cz9bx7d52c.
1#file-bd678698-6718-4979-8b9e-1b0f7645884e). Kinases were produced either as fusions to T7 phage3, or were expressed as
fusions to NF-kB in HEK293 cells and subsequently tagged with DNA for PCR detection18. In general, full-length constructs were
used for small, single-domain kinases, and catalytic domain constructs including appropriate flanking sequences were used for
multidomain kinases. Briefly, for the binding assays, streptavidin-coated magnetic beads were treated with biotinylated affinity li-
gands to generate affinity resins. The liganded beads were blocked to reduce nonspecific binding and washed to remove unbound
ligand. Binding reactions were assembled by combining kinase, liganded affinity beads and test compounds prepared as 100 3
stocks in DMSO. DMSO was added to control assays lacking a test compound. Primary screen interactions were performed in
384-well plates, whereas KD determinations were performed in 96-well plates. Assay plates were incubated at 25
C with shaking
for 1 h, and the affinity beads were washed extensively to remove unbound protein. Bound kinase was eluted in the presence of non-
biotinylated affinity ligands for 30 min at 25C with shaking. The kinase concentration in the eluates was measured by quantitative
PCR. KD values were determined using 11 serial threefold dilutions of test compound and a DMSO control.
N-(6-(3-((N,N-diethylsulfamoyl)amino)phenyl)-1H-indazol-3-yl)cyclopropanecarboxamide (SGC-AAK1-1)
3-Aminophenylboronic acid pinacol ester (1 eq., 50 mg, 0.228 mmol) in pyridine (1.2 mL) was cooled to 0C in an ice bath. Diethyl-
sulfamoyl chloride (2.06 eq., 80.7 mg, 0.0754 mL, 0.47 mmol) was added drop wise, and the reaction mixture was stirred overnight.
The reaction progress was checked by TLC, revealing complete consumption of startingmaterial (SM). Solvent was removed and the
residue was partitioned between dichloromethane and saturated aqueous sodium bicarbonate solution. The organic phase was
dried (Na2SO4), filtered and concentrated. The residue was purified using an Isco Combiflash companion automated purification sys-
tem (4g (18 mL/min), SiO2, 80%/20% to 25%/75% heptanes/EtOAc) to give diethyl({[3-(tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]
sulfamoyl})amine as an orange solid (44 mg, 54%), which was determined to be desired product by 1H NMR.
The following was added to a microwave vial: N-(6-bromo-1H-indazol-3-yl)cyclopropanecarboxamide (1 eq., 20 mg,
0.0677 mmol), diethyl({[3-(tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]sulfamoyl})amine (1 eq., 24 mg, 0.0677 mmol), and Pd(dppf)
Cl2 (10%, 4.96 mg, 0.00677 mmol) in a mixture of dioxane (0.19 mL) and 1M aq sodium carbonate (0.16 mL). The vial was capped
and heated in themicrowave at 120C for 30mins. Once cool, the reaction progress was examined by TLC, which revealed completee5 Cell Reports 26, 79–93.e1–e8, January 2, 2019
consumption of SM. The mixture was filtered through Celite and washed with EtOAc (ethyl acetate). The combined organic
solution was washed with brine, dried (Na2SO4), filtered and concentrated. The residue was purified using an Isco Combiflash com-
panion automated purification system (4g (18 mL/min), SiO2, 75%/25% to 20%/80% heptanes/EtOAc) to give SGC-AAK1-1 as a
yellow solid (14.3 mg, 49%): 1H NMR (400 MHz, Methanol-d4) d 7.80 (d, J = 0.8 Hz, 1H), 7.58 (s, 1H), 7.48 (dt, J = 0.8, 2.1 Hz, 1H),
7.38 – 7.35 (m, 2H), 7.33 (d, J = 8.5 Hz, 1H), 7.17 – 7.12 (m, 1H), 3.29 (d, J = 1.6 Hz, 4H), 1.91 (tt, J = 4.5, 8.0 Hz, 1H), 1.05 (t,
J = 7.1 Hz, 6H), 1.01 (dt, J = 3.0, 4.4 Hz, 2H), 0.95 – 0.88 (m, 2H); 13C NMR (101 MHz, Methanol-d4) d 174.1, 142.1, 141.9, 139.8,
139.0, 129.1, 122.2, 121.6, 119.7, 118.3, 118.1, 107.5, 48.2, 41.6, 13.5, 12.5, 6.8.
General procedure for preparation of 3-acylamino-6-bromoindazoles
To a solution of 6-bromo-1H-indazol-3-amine (48mg, 0.23mmol) in pyridine (0.75mL) was added cyclopropanecarboxylic acid chlo-
ride (0.021 mL, 0.23 mmol, 1 eq.,) drop wise at 0 C. The reaction mixture was stirred at this temperature for 4 hr and then allowed to
warm to room temperature. Once the reaction was complete the solvent was removed under reduced pressure. The residuewas then
dissolved in N,N-dimethylformamide and water was added drop wise. The precipitated solid was then washed with hexanes 3 times
and further dried to afford N-(6-bromo-1H-indazol-3-yl)cyclopropanecarboxamide (40.4 mg, 64% yield).
General procedure for 3-acylamino-6-arylindazoles
The following was added to a microwave vial: N-(6-bromo-1H-indazol-3-yl)cyclopropanecarboxamide (344 mg, 1.12 mmol)
dissolved in dioxane (4mL) and 1M Na2CO3 (1mL). To this solution, the following was added: 3-aminophenylboronic acid pinacol
ester (269 mg, 1.12 mmol, 1.0 eq.,), Pd(dppf)Cl2 (100.3 mg, 0.123 mmol, 0.1eq,). The reaction was run in the microwave at 160
C
for 20 mins, at which time SM was consumed. The reaction mixture was poured into water and extracted 3 times with EtOAc.
The combined organic layers were dried over Na2SO4 and concentrated to dryness. The compound was then purified by flash
chromatography to afford N-(6-(3-aminophenyl)-1H-indazol-3-yl)cyclopropanecarboxamide (100 mg, 28% yield).
N-(6-(3-(cyclopropanesulfonamido)phenyl)-1H-indazol-3-yl)cyclopropanecarboxamide (25A)
To a solution of N-[6-(3-aminophenyl)-1H-indazol-3-yl]cyclopropanecarboxamide (67mg, 0.2292 mmol) in pyridine (1mL) cooled to
0 C, cyclopropanesulfonyl chloride (1eq, 32.22mg, 0.2292 mmol) was added drop wise. The reaction mixture was stirred at 0 C for
4 hr andwarmed to room temperature. After verification by LC/MS that SMhad been consumed, solvent was removed under reduced
pressure. The compound was then purified by high pressure liquid chromatography (HPLC) from 10% to 100% ACN/water + 0.05%
TFA to yield 25A (44.5mg, 49%yield). 1HNMR (400MHz,Methanol-d4) d 7.83 – 7.78 (d, J = 8.6 Hz, 1H), 7.61 – 7.54 (m, 2H), 7.46 – 7.30
(m, 3H), 7.29 – 7.23 (ddd, J = 7.7, 2.2, 1.3 Hz, 1H), 2.62 – 2.49 (tt, J = 8.0, 4.8 Hz, 1H), 1.95 – 1.84 (ddd, J = 12.5, 7.9, 4.2 Hz, 1H), 1.07 –
0.77 (m, 8H). 13C NMR (126 MHz, Methanol-d4) d 5.8 (2C), 8.4 (2C), 15.0, 30.5, 30.8, 109.1, 117.2, 121.2, 121.3, 121.4, 123.1, 124.7,
130.8, 140.1, 141.2, 143.4 (2C), 143.8, 175.6. MS+ (– ES API) - 397.1.
N-(6-(3-(cyclopropanesulfonamido)phenyl)-1H-indazol-3-yl)isobutyramide (SGC-AAK-1N):
1H NMR (400MHz, Methanol-d4) d 7.82 – 7.75 (d, J = 8.6 Hz, 1H), 7.62 – 7.54 (dt, J = 10.9, 1.5 Hz, 2H), 7.47 – 7.31 (m, 3H), 7.31 – 7.22
(ddd, J = 7.8, 2.2, 1.3 Hz, 1H), 2.84 – 2.69 (hept, J = 6.8 Hz, 1H), 2.61 – 2.50 (tt, J = 8.0, 4.8 Hz, 1H), 1.29 – 1.15 (d, J = 6.8 Hz, 6H), 1.14 –
0.82 (m, 4H). 13C NMR (126 MHz, Methanol-d4) d 5.8 (2C), 20.0 (2C), 30.5, 36.3, 109.2, 117.4, 121.3, 121.4 (2C), 123.0, 124.7, 130.8,
140.1, 141.2, 141.3, 143.4, 143.8, 179.3. MS+ (– ES API) - 399.1.
Cloning, protein expression and purification
For crystallization of BMP2K, a construct of BMP2K residues 38-345 (NCBI NP_942595) encompassing the kinase domain with
surface mutations K320A and K321A in expression vector pNIC-Zb was used (Sorrell et al., 2016). The construct was trans-
formed into BL21(DE3) cells that co-express l-phosphatase and three rare tRNAs (plasmid pACYC-LIC+). The cells were
cultured in TB medium containing 50 mg/mL kanamycin and 35 mg/mL chloramphenicol at 37C with shaking until the
OD600 reached 3 and then cooled to 18C for 1 hour. Isopropyl b-D-1-thiogalactopyranoside (IPTG) was added to a final
concentration of 0.1 mM and the cultures were left overnight at 18C. The cells were collected by centrifugation then resus-
pended in 2x lysis buffer (100 mM HEPES buffer, pH 7.5, 1.0 M NaCl, 20 mM imidazole, 1.0 mM tris(2-carboxyethyl)phosphine
(TCEP), Protease Inhibitor Cocktail Set VII (Calbiochem, 1/500 dilution) and flash-frozen in liquid nitrogen. Cells were lysed by
sonication on ice. The resulting proteins were purified using Ni-Sepharose resin (GE Healthcare) and eluted stepwise in binding
buffer with 300 mM imidazole. Removal of the hexahistidine tag was performed at 4C overnight using recombinant TEV
protease. Protein was further purified using reverse affinity chromatography on Ni-Sepharose followed by gel filtration (Super-
dex 200 16/60, GE Healthcare). Protein in gel filtration buffer (25 mM HEPES, 500 mM NaCl, 0.5 mM TCEP, 5% [v/v] glycerol)
was concentrated to 12 mg/mL (measured by UV absorbance, using the calculated molecular weight and estimated extinction
coefficient, using a NanoDrop spectrophotometer (Thermo Scientific) using 30 kDa molecular weight cut-off centrifugal concen-
trators (Millipore) at 4C.Cell Reports 26, 79–93.e1–e8, January 2, 2019 e6
NanoBRET measurements
Constructs for NanoBRET measurements of AAK1 and BMP2K were kindly provided by Promega. The AAK1 construct represents
the short isoform of AAK1 with an N-terminal Nanoluc fusion, and the BMP2K construct represents residues the short isoform of
BMP2K with an N-terminal Nanoluc fusion. HEK293T cells (ATCC) were maintained in DMEM supplemented with 10% fetal bovine
serum (FBS) (Life Technologies) with penicillin and streptomycin. NanoLuc-AAK1 or NanoLuc-BMP2K fusion constructs were
complexed with Lipofectamine 2000 according to the manufacturer’s protocol (Invitrogen). DNA:Lipofectamine complexes were
formed with 24 mg DNA and 60 mL Lipofectamine. The transfection complexes were then mixed with HEK293T cells in a 100 mm
dish at 50%–70% confluence in serum-free DMEM (Lonza), followed by incubation in a humidified, 37C, 5% CO2 incubator. After
4 hr of incubation, the mediumwas replaced by 10% FBSDMEMwith antibiotics and the cells were incubated for an additional 20 hr.
The NanoBRET assaywas performed as previously described (Robers et al., 2015). Briefly, cells were trypsinized and resuspended in
Opti-MEMwithout phenol red (Life Technologies). Cells (85 mL) were then seeded into white, nonbinding surface plates (Corning) at a
density of 2 3 104 cells/well. Diluted tracer was prepared from 200 mM stock in Tracer Dilution Buffer (32.25% PEG400 in 12.5 mM
HEPESBuffer pH 7.5) at a 1 to 4 ratio, and 5 mLwas added to the cells to have a final concentration of 2, 1, 0.5 or 0.25 mM. All chemical
inhibitors were prepared as concentrated stock solutions in dimethylsulfoxide (DMSO) (Sigma-Aldrich). Serial dilutions of the inhib-
itors at 50x the final assay concentration were made by dilution with DMSO, before the inhibitors were added to the cells at 1:50 ratio
(2% final DMSO concentration). Cells were then incubated for 2 hr before Bioluminescence resonance energy transfer (BRET) mea-
surements. To measure BRET, NanoBRET NanoGlo Substrate (Promega) was added, and filtered luminescence was measure on a
BMG LABTECHClariostar luminometer equipped with 450 nmBP filter (donor) and 610 nm LP filter (acceptor), using 0.5 s integration
timewith gain settings of 3,600 for both filters. Background-corrected BRET ratios were determined by subtracting the BRET ratios of
samples with no tracer added.
Measurement of in vitro IC50 values for inhibition of AAK1 enzymatic activity
Enzymatic activity of AAK1 was monitored in 20 mL reaction volumes containing 25 nM AAK1 (27-365) in 15 mM MOPS pH 7.5,
2 mMMgCl2 and 0.004% Triton X-100 buffer plus 46 mM ATP (at Km) and 200 mM of an AP-2 derived peptide (biotin-GGSQITSQVTG
QIGWRR-amide). Optimal activity was achieved with sample incubation at 37C for 40 mins (steady-state conditions) in buffer
conditions that were tailored by factorial design using Design-Expert software (Stat-Ease, version 10). To generate inhibition curves,
end-point reactions were setup having compounds pre-incubated in a reaction mix without ATP for 10 mins at room temperature.
Next, all samples (in PCR tubes) were transferred to a PCR instrument set at 37C for another 5 mins. The reaction started with
the addition of 46 mM ATP (at Km), maintaining the incubation conditions for another 40 mins. The reactions were stopped and the
amount of ADP produced was measured using a coupled enzyme assay system that converts Amplex Red to Resorufin (Charter
et al., 2006). Fluorescence readings were made in a BMG Labtech Clariostar instrument with excitation peak set at 530 nm and emis-
sion peak reading at 590 nm.
Protein crystallization
The AAK1 inhibitor (dissolved in 100% DMSO) was added to the protein in a 3-fold molar excess and incubated on ice for approx-
imately 30 mins. The mixture was centrifuged at 14,000 rpm for 10 mins at 4C prior to setting up 150 nL volume sitting drops at three
ratios (2:1, 1:1, or 1:2 protein-inhibitor complex to reservoir solution). Crystallization experiments were performed at 20C. Crystals
were cryoprotected inmother liquor supplemented with 20%–25%glycerol before flash-freezing in liquid nitrogen for data collection.
Diffraction data was collected at the Diamond Light Source. The best diffracting crystals grew in 10% (v/v) Broad MW PEG smear,
3.2 MMgCl2, 100 mM HEPES pH 7.0 (Chaikuad et al., 2015). Data was collected at 100 K at the Diamond Synchrotron beamline I02.
Data collection statistics can be found in Table S5.
Isothermal Titration Calorimetry
AAK1 and BMP2K proteins were produced as previously described (Sorrell et al., 2016). Isothermal titration calorimetry measure-
ments were made on a Microcal VP-ITC instrument at 25C. For the interaction of AAK1 with SGC-AAK1-1, the compound was
diluted to 22 mM in ITC buffer from a stock at 10 mM in DMSO and loaded directly into the cell. AAK1 was dialyzed at 4C overnight
into ITC buffer (20 mMHEPES pH 7.5, 150 mMNaCl, 1 mM TCEP) and loaded into the ITC syringe at a final concentration of 218 mM.
Following thermal equilibration, AAK1 was titrated into the cell using serial injections of 8 mL until saturation was observed in the ther-
mogram. The same method was repeated for the BMP2K versus SGC-AAK1-1 interaction where protein was loaded into the syringe
at a concentration of 288 mMand injected into a 32 mMsolution of SGC-AAK1-1. The ITC data was analyzed with NITPIC (Keller et al.,
2012) and SEDPHAT (Zhao et al., 2015). The final fitted data values are in Table S4.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistics
All error bars are ± standard error (SE). Statistical significance was evaluated by Mann-Whitney t test unless otherwise stated.
N values are stated in figure legends. Each panel was performed in at least biological triplicate, with higher replicates noted in figure
legend. *** p < 0.0005, ** p < 0.005, * p < 0.05.e7 Cell Reports 26, 79–93.e1–e8, January 2, 2019
DATA AND SOFTWARE AVAILABILITY
Gain-of-function kinome screen
The reference number for the gain-of-function kinome screen reported in this paper is Mendeley Data (https://doi.org/10.17632/
352fxh8r6t.1).
KINOMEscan
The reference number for the KINOMEscan reported in this paper is Mendeley Data (https://doi.org/10.17632/cz9bx7d52c.1).
BMP2K KD bound to 25A
The reference number for the BMP2K KD bound to 25A is PDB: 5IKW.Cell Reports 26, 79–93.e1–e8, January 2, 2019 e8
